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The cytochrome P450 enzymes CYP101B1 and CYP101C1 from Novosphingobium aromaticivorans 
DSM12444 are homologues of the CYP101D1 and CYP101D2 enzymes from the same bacterium and 
CYP101A1 (P450cam) from Pseudomonas putida. Both enzymes can efficiently hydroxylate 
norisoprenoids and related substrates in combination with the same ferredoxin reductase, ArR and a 
[2Fe-2S] ferredoxin, Arx, electron transfer partners. Even though the physiological substrates for both 
the enzymes are yet to be confirmed, the crystal structure of CYP101C1 bound to -ionone and 
modelled structure of CYP101B1 has been generated. The Met82 residue of CYP101C1 aligns with the 
His85 residue of CYP101B1. In the crystallographic structure, this Met82 residue of CYP101C1, 
interacts with the carbonyl group of -ionone, which makes it an interesting site for mutation as these 
could potentially alter the activity and hydroxylation of norisoprenoid substrates. CYP101B1 oxidised 
-ionone with the highest product formation rate (1010 ± 60 min-1). The CYP101C1 enzyme oxidised 
-ionol with the highest product formation rate (1130 ± 30 min-1), whereas, the M82L-CYP101C1 
mutant enzyme had the highest product formation rate (790 ± 22 min-1) with -ionone. The selectivity 
for hydroxylation of norisoprenoids varies between CYP101B1 and CYP101C1. The M82L mutation 
however, did not change the selectivity for CYP101C1. For example, both -damascone and -ionone 
were hydroxylated at the C4 position by CYP101C1 and the M82L-CYP101C1 mutant. The CYP101B1 
enzyme displayed an altered selectivity and hydroxylated these substrates predominantly at C3 
position. When the substrate functional group was changed from a carbonyl to an alcohol (i.e. -ionol), 
the hydroxylation occurred preferentially at the C3 position with all three enzymes. By comparing the 
oxidation of -, - and - substituted damascones, we found that the alkene moiety present inside 
the cyclohexyl ring did have an effect on the selectivity of oxidation. The - substituted substrates are 
oxidised only at the C3 position by all three enzymes. The - substituted substrates are oxidised at C3 
position by CYP101B1 and at C4 position by CYP101C1 and M82L-CYP101C1. The - substituted 
substrate generates the 3,4-epoxide as the major product.  
To further explore the substrate range of CYP101B1 and CYP101C1, various substrates including cyclic 
ketones and cyclic esters were assessed to see if they induce enzyme activity and binding to the 
enzyme. The combinations of the best enzyme / substrates were then chosen to generate the 
oxidation metabolites in a larger quantity using whole-cell oxidation system to enable 
characterisation. The oxidation of 1-decalone by CYP101B1 generated a single major metabolite along 
with two minor products. The major product was characterized as 6-hydroxy-1-decalone and the 
minor product as 7-hydroxy-1-decalone. Comparison of the 1-decalone substrate to damascones, 
highlight the relationship of the oxidation metabolites 6-hydroxy-1-decalone to 4-hydroxy--
damascone and 7-hydroxy-1-decalone to 3-hydroxy--damascone. Oxacyclotridecan-2-one is oxidised 
by CYP101B1 on a carbon opposite to the carbonyl group. Along with these, muscone and 
cyclopentadecanone show a dissociation constant similar to -ionone with CYP101B1. However, the 
spin-state shift and activity induced by both of these substrates to CYP101B1 are comparatively 
smaller than -ionone. p-Tolyl acetate induced a large type-I spin-state shift and a weak binding to 
CYP101B1. It was oxidised at the benzylic methyl group, generating 7-hydroxy-p-tolyl acetate. 
Similarly, dihydroactinidiolide was also oxidised at the carbon opposite to the ester group generating 
6-hydroxy-dihydroactinidiolide. However, this substrate induces a very small spin-state shift and was 
oxidised with low activity by CYP101B1. None of the tested substrate showed a spin-state shift larger 
than 10% HS or increased activity with CYP101C1. 
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1.1 Background information on Cytochrome P450s 
 
Cytochrome P450 (CYPs or P450s) enzymes were first observed in 1958, independently by Garfinkel 
and Klingenberg. Each of them identified a CO-bound pigment at 450 nm in rat and pig liver 
microsomes [1, 2]. Later, keywork by Omura and Sato confirmed the haemoprotein nature of these 
pigments [3]. These enzymes make up a large superfamily of haem-dependent monooxygenases, 
which catalyse a diverse range of biological oxidative transformations. Enzymes are often favoured 
over chemical catalysts due to high energy efficiency and low environmental impact, specifically the 
absence of waste product. The high efficiency of CYP enzymes under mild conditions and their ability 
to catalyse numerous reactions has led to a significant body of research into the mechanisms of 
substrate binding and oxidation [4, 5]. 
CYP enzymes are found across all kingdoms of life, including bacteria, fungi, plants and mammals. In 
prokaryotic organisms, P450s are involved in a number of oxidation reactions while in eukaryotes, 
P450s are involved in a wide range of biosynthetic and biodegradative transformations which include 
the synthesis of steroids and xenobiotic metabolism [6]. Due to their characteristic reactions, these 
enzymes have been proposed as catalysts for the synthesis of fine chemicals and intermediates which 
are very difficult to synthesise using the usual chemical synthesis techniques. Enantioselectivity is an 
important concern when dealing with pharmaceuticals. For example; the thalidomide disaster in 1950 
where pregnant women were given thalidomide to treat nausea, but it was given as a racemic mixture. 
The R enantiomer was a sedative but the S enantiomer encouraged the release of alpha tumour 
“necrosis”, which caused more than 12,000 birth defects [7]. Cytochrome P450 enzymes could provide 
an enantio- and regio-selective route for hydroxylation reactions for the synthesis of fine chemicals. 
Poulos and team reported the first high resolution three dimensional structure of a P450 in 1987 [8]. 
It showed that the P450s contain a central iron (III) atom coordinated to four nitrogen ligand donors 
of porphyrin ring, a proximal cysteine (Cys) residue and a water molecule as the sixth ligand in the 
resting state (Figure 1.1) [9].  
 
Figure 1.1: Haem centre in P450 enzymes [9].  
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1.2 P450’s structure and characteristics 
 
In their resting ferric state, P450s absorb visible light at 419 nm, which accounts for their distinctive 
red colour. In “P450”, the “P” stands for pigment, whereas, the “450” is derived from the unique Soret 
absorbance band in the reduced CO-bound form of the enzyme [3, 4]. At the time of writing, more 
than 41,000 P450 enzymes have been named and categorised, although genome mining has revealed 
a total of more than 300,000 P450 sequences across all life kingdoms, majority of which remain 
uncategorised [10]. Systematic naming of members of the P450 superfamily is based on sequence 
similarity and in some instances function [11, 12]. The family to which P450s belong to is denoted by 
the number following its CYP prefix, this indicates the cytochrome P450 enzyme, and the subfamily is 
denoted by the subsequent numeral [13]. For example, the bacterial enzyme CYP101B1 from the 
bacterium Novosphingobium aromaticivorans, is a member of the family 101 and the first member 
identified for subfamily B [14]. CYP family members are defined as those with a similarity in amino 
acid sequence of > 40%, while subfamilies have members with similarity > 55% [15]. Although 
sequence conservation between P450 proteins of different families may be less than 20%, the overall 
structural fold is highly conserved between most P450 enzymes. However, the active site environment 
for substrate recognition differs significantly between P450s, which makes cytochrome P450 one of 
the most versatile superfamily of biological catalysts. Some bacterial P450s, such as P450cam from 
Psuedomonas putida, can be easily produced using Escherichia coli (E. coli) and hence, they have been 
researched extensively since their discovery [16-18]. The P450s derived from plant and animal cells 
are anchored in the cell membrane, and are often more difficult to express and purify. Furthermore, 
these P450s are prone to denaturing, which can make experiments employing these systems difficult 
to perform.  
Hydroxylation and C-H bond oxidation reactions are still one of the biggest challenges faced by the 
chemical and pharmaceutical industries, the reason being the unreactive nature of the saturated C-H 
bond. The approach used by industry currently requires high temperatures and pressures. 
Furthermore, the inorganic catalysts that are used are very expensive and often do not provide 
sufficient selectivity. The insertion of an oxygen atom from atmospheric dioxygen into an unactivated 
carbon-hydrogen bond within an organic substrate, is the primary function of P450s (Equation 1). This 
process occurs along with the formation of a H2O molecule. Commonly, the two electrons required 
for oxidation are derived from NADH or NAD(P)H (Nicotinamide Adenine Dinucleotide Phosphate), 
and these are transferred one at a time by electron transfer partner proteins (Equation 1).  
Along with mono hydroxylation, P450 enzymes are also able to perform other reactions such as 
dealkylation of methoxy and methylamino groups, oxidation of sulfur containing compounds, 
desaturation of alkyl chains and oxidation of alkenes and alkynes [19-22]. 
  
R-H + NAD(P)H + O2 + H
+  R-OH + NAD(P)+ + H2O (1) 
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1.3 Mechanisms followed during catalysis by Cytochrome P450s 
 
The distinguishing feature in the structure of P450 enzymes is the heme centre (iron porphyrin IX), 
which is attached to the rest of the enzyme via a proximal cysteine thiolate (Cys) ligand bound to the 
iron (Figure 1.1) [15]. The P450 catalytic cycle is largely conserved for all the members of the 
superfamily [5, 9]. The catalytic cycle of P450 enzymes begins with FeIII, with a water ligand 
coordinated to the 6th distal site (I), see Figure 1.2. Generally, this water ligand dissociates on substrate 
(R-H) binding (II). Next an electron sourced from NAD(P)H/NADH is supplied via electron transfer 
protein, which reduces the iron to FeII (III). This is followed by dioxygen binding to the FeII centre to 
form the dioxy complex (IV) followed by reduction by another electron (V). Protonation of the terminal 
oxygen atom (VI), then occurs which facilitates O-O bond heterolytic cleavage to form an iron(IV)-oxo 
porphyrin radical cation (VII) with release of a water molecule. The oxygen atom can now be inserted 
into the substrate via a radical rebound mechanism (Figure 1.3). The oxidised substrate now leaves 
the active site of P450 enzyme (VIII) while a water can now rebind to the distal site returning the 
enzyme to its resting state (I) [14].  
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The differences in the substrate range of P450s arises from the region around the enzyme active site. 
This also determines the overall chemical selectivity of the enzyme [9]. From the catalytic cycle (Figure 
1.2), it is evident that the electrons are of utmost importance for a catalytic cycle to function 
successfully. The selective oxidation of a single C-H bond inside a specific substrate, is the most 
renowned ability of P450 enzymes. This occurs because the enzyme can hold one C-H bond of the 
substrate in a close vicinity of the iron haem centre of the involved enzyme. This selectivity is the 
reason for the popularity of P450 enzymes, which cannot be replicated using conventional chemistry 
methods [9, 24]. 
Uncoupling reactions take place to either produce water via an oxidase pathway or hydrogen 
peroxide, this could result in inactivation of the P450 instead of forming the desired product (Figure 
1.4) [9, 10]. This uncoupling occurs, if the substrate is not held tightly in the active sight of enzyme. 
Due to this, even though a significant cycling of the catalytic cycle could be observed it would still not 
lead to the formation of product. 
 
Figure 1.4: Uncoupling pathway followed by P450s. 
The pathway that is followed by a reaction while hydrogen peroxide is produced, occurs during the 
reaction of a proton (H+) with the oxygen atom connected to the iron haem at the centre in the 
compound (VI) rather than terminal oxygen. This pathway is more likely to be followed when the active 
site of enzyme contains an excessive amount of water [9]. The oxidase pathway occurs when two 
additional protons and electrons are added to the reactive oxygen atom in compound I (VII) [9, 10]. 
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1.4 Electron transfer system of Cytochrome P450s 
 
The electron transfer in Cytochrome P450 is mediated by multiple protein transfer partner systems, 
in which reducing equivalents from NADH are transferred to haem via one or more electron transfer 
partner proteins. The nature and number of these electron transfer partners varies between 
organisms [25]. The electron transfer partner of P450s are divided into two general classes, class I and 
class II. The class I electron transfer system consists of two electrons transfer proteins, a flavin 
containing reductase (FAD), which transfers reduction equivalents from a pyridine nucleotide (i.e. 
NADH or NAD(P)H) to an iron-sulphur ferredoxin (Fe2S2 or FMN) (Figure 1.5). This system is observed 
mostly in bacterial and mammalian mitochondrial P450s [26]. Whereas, in class II electron system both 
FAD and Flavin mononucleotide (FMN) cofactors are present together in one protein, which transfer 
electrons to the P450 enzyme. Both the enzymes in class II system are membrane bound (Figure 1.5: 
Right).These are mostly observed in eukaryotic system [26]. 
 
Figure 1.5: Electron transfer systems of cytochrome P450s. Shown are classes I and II. Left: shows 
the bacterial class I system. Right: class II, a diflavin membrane-bound system [25]. 
 
Numerous CYP enzymes with potentially interesting and desirable activities have been discovered. 
However, many of these enzymes are orphaned due to the absence of electron partners (FAD or FMN) 
located nearby in the genome sequence [19, 27-29]. Close clustering of CYP genes and electron 
transfer partner such as those found for CYP101A1, CYP176A1 and CYP105D1, is an exception rather 
than a rule [30-33]. For example, of the 174 CYP gene discovered from 45 different Streptomyces 
species, only 18 are clustered with a ferredoxin gene [34]. In these organisms, the genes encoding all 
possible electron transfer proteins could be expressed and then assessed for activity [33]. 
Alternatively, a known ferredoxin-reductase/ferredoxin system can be recruited to reconstitute the 
activity of enzyme in in vitro and in vivo oxidation system but such cross-reactions between different 
P450 electron transfer chains are often slow [35-37]. Sixteen potential P450 monooxygenase genes 
have been identified so far, within the genome of Novosphingobium aromaticivorans [14, 19]. In 
addition, a class I electron transfer system, containing of a flavin-dependent ferredoxin reductase, ArR 
and a ferredoxin, Arx, has been successfully identified that is able to reconstitute the monooxygenase 
activity of CYP101B1, CYP101C1, CYP101D1 CYP101D2 and CYP111A2 [14, 19, 38]. Other than carrying 
and transferring electrons, electron transfer proteins can also have additional roles. For example, 
putidaredoxin (Pdx) has an effector role in CYP101A1 (P450cam) activity [39, 40]. Hence, in order to get 
an optimal catalytic activity, the identification of functional CYP electron transfer chains are often 
essential.  
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1.5 Oxidation of substrate by P450s 
 
The catalytic cycle of P450s uses a highly reactive oxidising species, the ferryl intermediate (Figure 1.2, 
Compound I). This is generally believed to be the oxygen activating species in most P450 catalysis. The 
role of Compound I in hydroxylation reaction of P450s, has been broadly studied [41-43]. However, 
experimental studies have shown that the electrophilic ferric-hydroperoxide (Compound 0 or VI, see 
Figure 1.2) and the nucleophilic ferric-peroxo anion (V) could also be responsible for some 
monooxygenase activity [42, 44-46]. For example, Compound 0 has been reported to catalyse alkene 
epoxidation [44, 46], while the peroxo-anion has been implicated in aldehyde oxidation [47].  
 
1.5.1 Hydrocarbon hydroxylation 
 
The hydroxylation reaction catalysed by P450 enzymes is believed to proceed via the radical or oxygen 
rebound mechanism (Figure 1.3), which was first proposed by Groves and McClusky in 1976 [23, 48]. 
In the first step, the highly reactive ferryl oxygen abstracts a hydrogen atom from the alkyl substrate 
generating a Fe(IV)-OH species (Compound II) and the substrate radical (Figure 1.3). This remains 
bound within the active site of the enzyme, where it immediately recombines with the hydroxyl radical 
derived from the Fe(IV)-OH intermediate to give the alcohol product (Figure 1.3) [23, 49]. 
To further understand the involved mechanism, radical clock substrates containing strained ring 
systems like cyclopropyl have been widely employed to determine the rate of radical rebound in C-H 
hydroxylation (Figure 1.6 (a)). These substrates undergo rapid ring-opening reactions at known rates 
via a radical intermediate. If rebound occurs at the initial site of H-abstraction, hydroxylation product 
results with a rate of kt (Figure 1.6 (a)). On the other hand, the radical can also go for rearrangement 
(kr) followed by trapping of the rearranged radical yielding a different hydroxylated product (Figure 
1.6 (a)). The ratio of these products together with the known rate constant of the rearrangement 
reaction enables the lifetime of the radical to be calculated. Using radical clocks, radical lifetimes (~50 
ps) were calculated for norcarane and bicyclo[2,1,0]pentane when oxidised by P450s like, CYP2B1, 
CYP2E1, P450cam and P450BM3 [50]. 
 
Figure 1.6 (a): Function of a methyl cyclopropane as a radical clock. Radical trapping (kt) and 
rearrangement (kr) resulting in different products.  
However, recent studies using ultrafast radical clock suggest that the norcrane radical has a 
significantly shorter lifetime 0.5-25 ps [51, 52]. Furthermore, several ultrafast clocks displayed shorter 
than expected radical lifetimes, which suggests that the radical to be a transition state not a reaction 
intermediate [53-56]. 
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A two-state reactivity model calculated that the hydroxylation can proceed via a radical or a cation 
intermediate character dependent on the dominant spin-state of the iron in Compound I (Figure 1.6 
(b)) [57]. Based on DFT calculations, the short radical lifetime observed in certain experiment is 
explained by barrier-free radical rebound pathway when Compound I is in the low spin state (doublet) 
and the longer lifetime due to the high energy barrier in the high spin state (quartet) (Figure 1.6 (b)). 
The energy barrier in the radical rebound mechanism for the high spin pathway leads to an alternate 
reaction involving a cationic intermediate, while this barrier for the low spin state is negligible. 
Consequently, if Compound I is in low spin state, the radical rebound mechanism is favoured (Figure 
1.6 (b)) [57]. 
 
Figure 1.6 (b): DFT-based mechanism for hydroxylation from high spin (HS: 4A2u, solid line) and low 
spin states (LS: 2A2u, dashed line) of Compound I. TS refers to the transition state [58-61]. 
Recently, a concerted catalytic mechanism has been proposed, which suggests that along with two-
state reactivity, it is also important to consider the way in which the enzyme controls the reaction 
trajectory [49]. The C-H abstraction and rebound phase of the hydroxylation can be brought closer 
together in time to generate a dynamically concerted mechanism. A reaction is considered as 
dynamically concerted if it consists of two bond forming / bond breaking processes and the time gap 
between the first and the second bond forming / bond breaking event is less 60 fs (which is the lifetime 
for a transition state with a zero-energy barrier). The reaction is considered to be dynamically stepwise 
if the time gap is longer than 60 fs [49].  
 
1.5.2 Epoxidation of alkenes 
 
Alkene epoxidation is also a common reaction catalysed by P450s which usually displays 
stereoselectivity. This suggests a concerted mechanism by the enzyme in which the ferryl oxygen 
interacts with both the carbon atoms of the alkene at the same time [62, 63] (Figure 1.7). 
Figure 1.7: The concerted mechanism of alkene epoxidation by Compound I [62, 63]. 
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Both Compound I and Compound 0, have been reported to be capable of epoxidation. The two-state 
reactivity model (TSR) of the low spin and high spin states of Compound I has been assessed [64]. The 
low spin state gives rise to the radical intermediate taking place due to the low energy barrier (Figure 
1.8). On the other hand, the high spin state has a higher energy barrier which increases the lifetime of 
the intermediate, which leads to a stereoselective product via a carbocation (Figure 1.8) [65-68]. 
Compound 0 has been reported to have a much larger barrier for epoxidation reactions compared to 
Compound I [64].  
 
Figure 1.8: Epoxidation of alkene by Compound I through a cationic (top) and radical (bottom) 
pathways. 
However, epoxides are not the only products that can arise from P450-catalysed alkene oxidation and 
rearranged products like aldehydes or ketones can also be observed. This could be explained by the 
transfer of an electron between a C-radical and Fe (IV) with the generation of a carbocation 
intermediate. In this case, the less substituted carbon binds to the Fe(IV)-oxyl and one substituent 
migrates to generate a ketone or aldehyde product (Figure 1.9) [65]. 
Figure 1.9: Mechanism of rearrangement product by P450 enzyme instead of epoxidation. 
 




CYP101A1, also referred as P450cam catalyses the selective oxidation of camphor to 5-exo-
hydroxycamphor (Figure 1.10) [69, 70]. This enzyme is extracted from the soil bacterium Pseudomonas 
putida [69, 70]. Since its discovery in 1968, it has been used extensively to study the general 
mechanism of P450s [70, 71]. P450cam was the first bacterial P450 enzyme to be successfully expressed 
using E. coli. and isolated recombinantly for in vitro oxidation turnover studies [16, 17]. P450cam uses 
a class I electron transfer system with two electron transfer partners, a FAD containing putidaredoxin 
reductase (PdR) and a [2Fe-2S] putidaredoxin ferredoxin (Pdx) [25].  
 
Figure 1.10: Conversion of camphor to 5-exo-hydroxycamphor by P450cam. 
The reported crystallographic structure of P450cam (PDB ID: 3WRH) (Figure 1.11) is of interest for 
protein engineering studies [8]. Many crystallographic studies of this enzyme have enhanced our 
understanding regarding which active site residues are responsible for the biocatalytic selectivity of 
P450cam [72, 73]. This led to the development of mutated P450cam enzymes by substituting alternative 
residues in the active site. This optimisation improved the biocatalytic activity towards different 
substrates. For example, P450cam naturally binds to camphor and exclusively oxidises it to 5-exo-
hydroxycamphor as the sole biproduct (Figure 1.10). However, the bicyclic compound (+)--pinene, 
which has structural similarity with (+)-camphor, the selectivity for the oxidation by P450cam is much 
lower, it generates minor products along with the expected product, (+)-verbenol [74] (Figure 1.12).  
Figure 1.11: Crystal structure of camphor bound CYP101A1 (P450cam) (PDB ID: 3WRH) [8]. 
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Figure 1.12: Products from (+)--pinene oxidation catalysed by P450cam [74]. 
 
1.6 P450 enzymes from Novosphingobium aromaticivorans.  
 
Novosphingobium aromaticivorans DSM12444, is a gram-negative aerobic bacterium. It possess 
sixteen genes that encode for P450 enzymes which are capable of oxidising a wide variety of 
substrates including terpenes, linear alkanes and polyaromatic hydrocarbons [14, 75, 76]. This range 
of substrates of monooxygenase enzymes of N. aromaticivorans is believed to be due to the need of 
bacteria to metabolise xenobiotic compounds present in its environment in order to grow [77]. The 
sixteen P450s of this bacterium were classified into ten different families which includes CYP101 and 
CYP111 [19, 77]. The four CYP101 member and CYP111 use a common class I electron transfer system 
(Figure 1.5), which consists of a FAD containing ferredoxin reductase (ArR) and a [2Fe-2S] ferredoxin 
(Arx) [19]. The physiological electron transfer partner of five enzymes (CYP101B1, CYP101C1, 
CYP101D1, CYP101D2 and CYP111A2) have been successfully produced using E. coli [14, 19]. E. coli 
has also been used as a host for whole cell oxidation using these enzymes for the formation of product 
at a gram per litre scale. Therefore, these enzyme systems are suitable for use in larger scale 
biocatalysis [19]. It is of noteworthy that the gene for CYP101B1 is located on a plasmid, whereas those 
of CYP101C1, CYP101D1, CYP101D2, along with ArR and Arx, are on the chromosomal genomic DNA 
[14, 19]. 
 
Figure 1.13:  Oxidation of camphor by P450cam, CYP101D1 and CYP101D2. 
CYP101A1 (P450cam) belongs to the same family as these CYP101 enzymes. Selective camphor 
hydroxylation is also observed with both the CYP101D1 and CYP101D2 enzymes (Figure 1.13) [14, 19]. 
However, in case of CYP101B1, camphor is oxidised to form 5-exo-hydroxycamphor as the major 
product along with the formation of four separate metabolites in minor quantities (Figure 1.14) [14]. 
Instead of camphor, CYP101B1 has been reported to selectively oxidise -ionone to 3-hydroxy--
ionone with higher activity and binding affinity (Figure 1.14) [14]. -Ionone induces a large type-I spin 
state shift of > 95% and a tight dissociation constant of Kd = 0.23 μM [76].  
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Figure 1.14: Oxidation of camphor (top) and -ionone (bottom) by CYP101B1. The product distribution 
is given in percentage. 
CYP101C1, which is also from N. aromaticivorans, is a homologue of P450cam (CYP101A1) and 
CYP101B1. It shares the same electron transfer partner (ArR/Arx) with CYP101B1 and use a class I 
electron transfer system [78]. Even though CYP101C1 shares 43% sequence identity with P450cam, it 
displays minimal activity for camphor oxidation [78]. However, like CYP101B1, CYP101C1 also oxidises 
norisoprenoid substrates [14]. Even though, CYP101C1 oxidises -ionone to generate the same 
metabolites as CYP101B1, its selectivity is altered to generate the 4-hydroxy--ionone as the major 
product (Figure 1.15) [14]. 
 
Figure 1.15: Oxidation of -ionone by CYP101C1. The product distribution is given in percentage. 
The crystal structure of CYP101A1, CYP101C1, CYP101D1 and CYP101D2 have been solved but not for 
CYP101B1. The crystal structure of CYP101C1 bound to -ionone (Figure 1.16) has been reported, 
which shows that it has a open conformation with an access channel in similar position to those found 
in CYP101A1 [78]. However, the structure of CYP101C1 displays various differences at the active site, 
and the proximal face [78]. The crystal structure of -ionone bound CYP101C1 shows that the 
substrate is in van der Waals contact with majority of the active site residues, and that the butenyl 
side chain is pointing away from the heme [78]. There is an interaction between the carbonyl group 
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of the substrate with the Met82 residue, this suggest that the Met82 active site might help orient the 
substrate. 
Figure 1.16: Crystal structure of -ionone bound CYP101C1 (PDB ID: 3OFU) [78]. 
 
1.7 Thesis objective 
 
In this thesis we will study the activity and selectivity of CYP101C1 enzyme on addition of 
norisoprenoid substrates. Using protein engineering, site specific mutation was performed on 
CYP101C1 enzyme to generate the M82L-CYP101C1 mutant variant with the intention of investigating 
the effect of this change on the activity of norisoprenoid substrates. This mutated enzyme will be 
tested alongside both wild type CYP101C1 and CYP101B1 enzyme to identify the change in selectivity. 
The whole-cell system will also be used to synthesise the metabolites in a larger quantity for 
characterisation. 
Furthermore, the CYP101B1 and CYP101C1 enzyme has been reported to efficiently oxidise various 
other substrates like cyclic ketones, cyclic esters and monoterpenoids. To further explore the potential 
of these enzymes to be used as biocatalysts for other valuable chemical or drug metabolite synthesis, 
they will be tested with a series of compounds which contains ester, ketone, amide and other similar 
functional groups. This will give us the data to explore the substrate range of both CYP101B1 and 
CYP101C1. The best suited substrate to the enzyme will then be studied extensively using whole-cell 
turnover.  
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Substrates, solvents and the reagents were purchased from Merk (Australia), Tokyo Chemical Industry 
(Tokyo), Australian Botanical Products (Australia), Alfa Aesar (United Kingdom) and Flurochem (United 
Kingdom). Biological reagents such as antibiotics, dithiothreitol (DTT) and isopropyl β-D-1-
thiogalactopyranoside (IPTG) were purchased from Anachem (Astral Scientific, Australia) or Biovectra 
(Scimar, Australia). 
 
 2.2 Cell culture media and Buffer solutions 
 
Media and buffers used for bacterial growth and whole-cell turnovers were as follows (all reagent 
quantities listed below are for one litre of media in MQ water): 
Super Optimal broth with Catabolite repression (SOC): 
• Tryptone (20 g) 
• Yeast extract (5 g) 
• MgCl2 (1 g) 
• NaCl (0.5 g) 
• KCl (0.2 g) 
• 0.2% w/v glucose 
Lysogeny Broth (LB): 
• Tryptone (10g) 
• Yeast extract (5g) 
• NaCl (10g) 
20X PBS† (pH = 7.2): 
• NaCl (160 g) 
• KCl (4 g) 
• Na2HPO4 (2.88 g) 
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Trace Elements: 
• Na2EDTA (20.1g) 
• FeCl3.6H2O (16.7g) 
• CaCl2.H2O (0.74g) 
• CoCl2.6H2O (0.25g) 
• ZnSO4.7H2O (0.18g) 
• MnSO4.4H2O (0.132g) 
• CuSO4.5H2O (0.10g) 
E. Coli minimal media (EMM): 
• K2HPO4 (7g) 
• KH2PO4 (3g) 
• (NH4)2SO4 (1g) 
• Na3Citrate (0.5g) 
• MgSO4 (0.1g) and 20% w/v glucose (20mL) were added after autoclaving. 
Tris buffer† (1M stock) (pH = 7.4): 
• Tris(hydroxymethyl)aminomethane (121.1 g) 
†pH adjusted using HCl or NaOH 
For LB media, antibiotics were added to working concentrations: of 100 μg/mL and 30 μg/mL for 
ampicillin (amp) and kanamycin (kan) respectively. 
UV/Vis spectroscopy was performed on a Varian Cary 60 spectrophotometer (Agilent), and the assays 
were recorded at 30 ± 0.5˚C. Details of gas chromatography-mass spectrometry (GC-MS) and gas 
chromatography (GC) analyses, methods, columns and instrument conditions are provided in Table 
1.1. High performance liquid chromatography (HPLC) analyses were performed using a Shimadzu 
HPLC, in combination with six different units comprising of a DGO-20AR degassing unit, two LC-20AR 
solvent delivery modules, CBM-20A/20Alite system controller, SIL-20ACHTUFLC autosampler, SPD-
M20A photodiode array UV-Vis detector (monitored between 250 to 400 nm range) and a FRC-10A 
fraction collector connected to a straight phase silica column (250 mm x 10 mm, 5 μm). The products 
were separated using a 5-70% isopropanol-hexane gradient with 3 mL min-1 flow rate over 38 minutes.   
NMR spectra were acquired on an Agilent DD2 spectrometer operating at 500 MHz for 1H and 126 
MHz for 13C or a Varian Inova-600 spectrometer operating at 600 MHz for 1H and 151 MHz for 13C. A 
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Table 1.1: GC and GC-MS operating conditions 
GC-MS Shimadzu GC-2010 coupled with GC-MS-QP2010S detector 
Column SPB5 MS fused silica column 
(30 mm x 0.25 mm x 0.25 μm) 
Column carrier gas 
Injector and interface temperature 
Helium (flow rate 1.3 ml-1) 
250 ˚C and 280 ˚C  
Oven Method for norisoprenoids 120 ˚C (hold 3 min), 10 ˚C min-1 to 240 ˚C (hold 5 min) 
Oven Method for sesquiterpenes 160 ˚C (hold 3 min), 5 ˚C min-1 to 250 ˚C (hold 4 min) 
Column  Rtx-5 MS fused silica column  
(30 mm x 0.25 mm x 0.25 μm) 
Column carrier gas 
Injector and interface temperature 
Helium (flow rate 1.3 ml min-1) 
250 ˚C and 280 ˚C  
Oven Method for Norcarane ester and 
norcarane alcohol 
120 ˚C (hold 3 min), 9 ˚C min-1 to 240 ˚C  
GC  Shimadzu Nexis GC-2030 coupled to flame ionisation detector (FID) 
Column Agilent DB-wax UI column 
(30 mm x 0.25 mm x 0.25 μm) 
Column carrier gas 
Injector and FID temprature 
Helium (flowrate 1.3 ml min-1) 
250 ˚C 
Oven Method for Norisoprenoids  160 ˚C (hold 3 min), 5 ˚C min-1 to 220 ˚C 
 
2.3 Whole-cell turnovers 
 
DNA vectors pETDuet containing ferredoxin reductase (ArR) and ferredoxin (Arx) genes and pRSFDuet 
harbouring the appropriate CYP101B1 or CYP101C1 gene with Arx were transformed into BL21(DE3) 
(40 μL) Escherichia coli (E. coli) cells and kept on ice for 1 h [19]. The sample was then heat shocked at 
42˚C for 1 min before being returned to the ice for 2 min. SOC media (150 μL) was added to the sample, 
which was shaken at 37˚C at 200 rpm for 1 h. The solution was then spread onto an LBamp/kan antibiotic 
plate and heated at 37˚C for 5 min with the lid partially open to get rid of any residual liquid. The plate 
was inverted and incubated at 37˚C overnight. A single colony was removed and grown in LBamp/kan 
(500 mL) supplemented with kanamycin (0.1% v/v from 30 μg/mL stock solution) and ampicillin (0.1% 
v/v from 100 μg/mL stock solution) antibiotics and grown at 37˚C at 120 rpm for 8 h. The temperature 
was decreased to 18˚C over 30 mins, followed by the addition of ethanol (2% v/v), benzyl alcohol 
(0.02% v/v) and trace element solution (1.5 mL). Protein production was induced by adding IPTG (100 
μL of 0.1 M stock solution). The culture was then incubated for a further 48 to 72 h at 18˚C and 90 
rpm. Cells were harvested by centrifugation (5000g, 10 min, 4˚C) and resuspended in EMM media (1 
L per 500 mL of culture). The resuspended cells were split and 200 mL aliquots were transferred to a 
2 L baffled flask and substrate (1-2 mM) was added. The flask was then shaken at 30˚C and 160 rpm 
for 2 h. Two aliquots of substrate (2 mM) were added at an interval of 2 h. Additional glucose (2 mL 
from 20% v/v solution) and phosphate-buffered saline (20x PBS, 2.5% v/v) was added with the last 
aliquot and continued to incubate for 8 h before the cells were removed from the supernatant by 
centrifugation (5000 g, 10 min, 4˚C). 
The supernatant from the whole-cell turnover was extracted in ethyl acetate (3 x 100 mL), washed 
with brine (100 mL) and dried using sodium sulphate (Na2SO4). The organic extracts were pooled and 
the solvent was removed under reduced pressure. The UV inactive substrate and their metabolite 
were loaded onto a silica column for flash chromatography using a hexane/ethyl acetate stepwise 
gradient ranging from 85:15 to 20:80 hexane to ethyl acetate system using 1.5% increase in ethyl 
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acetate every 50 mL. The composition of the fractions was assessed by TLC and GC and those 
containing a single product were combined for characterisation. The solvent was removed under 
reduced pressure again.  
The UV active substrates and their metabolites were purified using HPLC with a straight phase silica 
column (250 mm, 10 mm; 0.5 μm) using a binary gradient 10:90 to 70:30 isopropanol to hexane 
system. The solvent was then removed under reduced pressure and then a stream of nitrogen. The 
purified products (ranging from 4~15 mg) were dissolved in CDCl3 with tetramethyl silane (TMS) and 
the organics analysed by NMR spectroscopy.  
 
2.4 Enzyme Purification 
 
2.4.1 Purification of CYP101B1 and CYP101C1 
 
BL21(DE3) E.coli. competent cells were transformed with a plasmid vector (pET26; Merck Milipore, 
United States) harbouring the appropriate CYP101B1 and CYP101C1 gene and grown on LBkan plate 
[14]. A single colony was added to each flask of LBkan (500 mL in 2 L conical flask) and incubated at 37˚C 
at 120 rpm for 8 h. The temperature was decreased to 18˚C over 30 min. Ethanol (2% v/v) and benzyl 
alcohol (0.02% v/v) were then added. The culture was allowed to shake for another 20 min and then 
protein expression was induced with 0.1 mM IPTG. The culture was further incubated for 48 to 72 
hours at 18˚C and 90 rpm. Cells were harvested by centrifugation (5000g, 10 min, 4˚C) and stored 
before purification at -20˚C. Pallets were resuspended in 50 mM Tris buffer (pH 7.4, 250 mL) containing 
1 mM DTT (buffer T) and lysed by sonication (Autotune CV334, Sonics and Materials, United States) 
using 80 x 20 s pulses with 40 s intervals. The resulting suspension was immediately centrifuged (40000 
rpm, 25 min, 4˚C) to remove cell debris and the pellet was discarded. The supernatant was then loaded 
onto a DEAE Sepharose column (XK50, 200 mm x 40 mm; GE Healthcare,US), and purified using a 
gradient from 100 to 250 mM KCl in buffer T at a flow rate of 6 mL min-1. Red coloured fractions were 
combined and concentrated by ultrafiltration (10 kDa exclusion membrane). The concentrated protein 
was desalted using a Sephadex G-25 medium grain column from (200 mm x 40 mm; GE Healthcare), 
eluted using buffer T. 
The desalted protein was concentrated and loaded onto a Source-Q ion exchange column (XK26, 80 
mm x 30 mm; GE Healthcare) linked to an AKTA Pure (GE Healthcare), and eluted using a linear 
gradient from 0 to 500 mM KCl in buffer T. Fractions with A419/A280 > 2 were collected and concentrated 
using an ultrafiltration cell with a 10 kDa exclusion membrane until the P450 reached approximately 
10 mL volume. The solution was then centrifuged (5000 g, 10 min, 4˚C) to remove any debris. The 
protein was mixed with an equal amount of 80% glycerol and then filtered using a 0.22 μm syringe 
filter and stored at -20˚C. The extinction coefficients of CYP101B1 and CYP101C1 were reported as 
𝜀417 = 113 mM
-1 cm-1 and 𝜀417 = 121 mM
-1 cm-1, respectively and were henceforth used to determine 
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2.4.2 Purification of ArR (Ferredoxin Reductase) 
 
BL21(DE3) E.coli. competent cells (30 μL) were transformed with pET26 vector containing ArR gene 
and grown on a LBkan antibiotic plate overnight at 37˚C [19]. Four of the grown colonies were picked 
and added to four separate LBkan (4 X 500 mL) solutions. The culture was then incubated and harvested 
as described in section 2.4.1. The cell pellets were then resuspended in 50 mM buffer T (pH 7.4, 200 
mL). The cells were then lysed via sonication (Autotune CV334) using 80 x 20 s cycle with 40 s intervals. 
The resulting suspension was centrifuged (37,000 g, 20 min, 4˚C) to discard any cell debris and the 
yellow coloured supernatant containing the protein was retained. 
The protein was loaded onto a DEAE Sepharose Column (XK50, 200 mm x 40 mm; GE healthcare) using 
a gradient from 100mM to 400mM KCl in buffer T at a flow rate of 6 mL min-1. The yellow coloured 
fractions were combined and concentrated by ultrafiltration (10 kDa exclusion membrane). The 
concentrated protein was then desalted using a Sephadex G-25 medium grain column (250mm x 40 
mm; GE Healthcare) using buffer T. Desalted protein was further purified using a Source-Q ion 
exchange column (XK26, 80 mm x 30mm; GE Healthcare) using a linear gradient from 0 to 400 mM KCl 
in buffer T. The yellow coloured fractions with A280/A458 < 8 were combined together and concentrated 
using ultrafiltration until the ArR reached an approximate volume of 10 mL. The concentrated protein 
was centrifuged (5000 g, 10 min, 4˚C) to remove any particulate matter and diluted with an equal 
amount of 80% glycerol before filtering with a sterile 0.22 μm syringe filter and stored at -20˚C. The 
ArR concentration was estimated using extinction coefficient, 𝜀458 = 10 mM
-1 cm-1, which were 
henceforth used to determine the concentration of the enzyme [19]. 
 
2.4.3 Purification of Arx (Ferredoxin) 
 
DNA vector pRSFDuet-Arx was transformed into BL21(DE3) E. coli. Competent cells (40 μL) and grown 
on an LBkan antibiotic plate at 37˚C overnight [19]. A single colony was then removed and added to a 
flask of 500 mL of LBkan media and incubated at 37˚C and 120 rpm overnight. The culture was incubated 
to produce protein and harvest cell pellets as described in section 2.4.1. The cell pellets were 
resuspended in 10 mM buffer T (pH 7.4, 300 mL) containing 1 mM DTT, 20% v/v glycerol, 1% v/v 2-
mercaptoethanol, 300 mg lysozyme, 2 mL Trixton X-100 and 2 mL Tween 20. Resuspended cells were 
stirred for 30 min at 4˚C. The cells were lysed by sonication using 80 x 20 s pulses with 40 s interval. 
The resulting suspension was centrifuged (37000 g, 20 min, 4˚C) to remove the cell debris. Brown 
supernatant was collected and loaded onto a DEAE Sepharose column (XK50, 200 mm x 40 mm; GE 
Healthcare) and the protein was eluted using a salt gradient of 100 to 400 mM KCl in buffer T at a flow 
rate of 6 mL min-1. Brown coloured fractions containing ferredoxin were then collected and 
concentrated by ultrafiltration (10 kDa exclusion membrane). The concentrated protein was desalted 
using Sephadex G-25 medium grain column (200 mm x 40 mm) pre-equilibrated with buffer T (pH 7.4, 
50 mM). The desalted protein was further purified using a Source-Q ion-exchange column (XK26, 80 
mm x 30 mm; GE Healthcare) with elution using a gradient from 0 to 200 mM KCl in buffer T (pH 7.4, 
50 mM) at a flow rate of 6 mL min-1. Fractions with A415/A280 > 0.6, were collected and concentrated 
using ultrafiltration (10 kDa exclusion membrane). The concentrated protein was then centrifuged 
(5000 g, 10 min, 4˚C) to get rid of any particulate matter which was then diluted with an equal amount 
of 80% glycerol. The protein was then filtered with a sterile 0.22 μm syringe filter and stored at -20˚C. 
The concentration for Arx was calculated using 𝜀415= 9.2 mM
-1 cm-1 and were henceforth used to 
determine the concentration of Arx [19]. 
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2.5 Spin-State Shift 
 
The relevant P450 enzyme was diluted to ~3 μM concentration with 50 mM Tris buffer (pH 7.4). The 
UV-Vis spectrum was recorded from 600 to 250 nm. Aliquots of the substrate (0.5 μL from 100 mM 
stock solution in ethanol) was added to 600 μL of the enzyme solution and their spectrum was 
recorded. Further addition of substrates was made till the shift from low spin (420 nm) to high spin 
(390 nm) did not change. For example, -damascone induces a type-I spin-state shift of 80% HS to 
CYP101B1 (Figure 2.1 (a)). The percentage of high-spin (HS) state shift induced by the substrate was 
estimated by comparing different properties of the spectra of camphor free and camphor bound 
P450cam (CYP101A1; Figure 2.1(b)). 






















Figure 2.1 (a): Spin-state shift of CYP101B1 in -damascone free (black) and bound (80% HS) form 
(red) of CYP101B1. 
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Figure 2.1 (b): Spin state shift diagram for P450cam in camphor free/bound state from 0% to 100%. 
 
2.6 Dissociation constant 
 
Dissociation constants (Kd) were determined to measure how tightly different substrates bind with the 
enzyme. The respective P450 enzyme was diluted to ~1 μM with 50 mM buffer T (pH 7.4, 2.5 mL). The 
UV-Vis spectrum between 600 nm to 300 nm was recorded and used to baseline the spectrometer. 
Increasing aliquots (1-5 μL) of 1 mM stock solution (in ethanol) of the substrate was added to the 
enzyme and the spectra was recorded. A maximum of 10 μL of 1 mM of substrate was added, to make 
sure the enzyme concentration was not diluted. Further aliquots (1-5 μL, cumulative of 10 μL in total) 
of substrate from 10 mM stock solution (in ethanol) were added and the spectra recorded. Finally, 
aliquots of 100 mM stock solution were added until the peak to trough absorbance difference was 
constant. The peak to trough absorbance difference was plotted against the concentration of 
substrate to determine the dissociation constant of the substrate with the enzyme and fitted to 




                                     (Eq. 2.1)    
Where, ΔA represents the absorbance difference between the peak and the trough, ΔAmax is the 
maximum absorbance difference, [S] is the substrate concentration and Kd is the dissociation constant 
If the dissociation constant is less than five times the enzyme concentration (Kd < 5[E]), the assumption 
used to derive the equation (Eq 2.1) becomes invalid. Rather, the tight binding quadratic equation 
(Morrison equation 2.2) must be used to determine the dissociation constant (Eq 2.2) [81]. 





[E] + [S] + Kd −  √([E] + [S] + Kd)
2 − 4[E][S]
2[E]
              (Eq 2.2) 
Where ΔA represents the peak to trough difference, ΔAmax represents the maximum peak to trough 
difference, [E] is the enzyme concentration, [S] is the substrate concentration and Kd is the dissociation 
constant. 
Three sets of data were collected to determine the Kd value for each substrate. The error in Kd is based 
on the range of values produced from this curve of best fit (Figure 2.2). 





























Figure 2.2 Dissociation constant example CYP101B1 + -damascone (Kd = 3.7 ± 0.3 μM)  
 
2.7 In vitro Turnovers and NADH consumption rates 
 
The respective P450 enzyme (0.5 μM), Arx (5 μM), ArR (1 μM), bovine liver catalase (12 μL of 10 mg 
mL-1 stock in glycerol) and oxygenated 50 mM Tris (pH 7.4) were combined to a volume of 1.2 mL in a 
cuvette. The mixture was equilibrated at 30˚C for 1 min and NADH (A340 ≈ 2, 320 μM) was added from 
a 20 mg mL-1 stock and the absorbance at 340 nm was recorded for the remainder of the experiment 
(Figure 2.3 (a)). After 1 minute, substrate (1 mM, 100 mM stock in EtOH) was added. The gradient of 
the plot and A340 against time was used to calculate the rate of NADH consumption using the extinction 
coefficient, 𝜀 = 6.22 mM-1 cm-1.  
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(a) β-damascone in vitro turnover with 
CYP101C1 






















(b) Calibration curve for β-damascone 
R2 = 0.998; m = 0.0094 
Figure 2.3 Example of NADH turnover assay and calibration curve. 
In vivo and in vitro turnovers were analysed via HPLC/GC/GC-MS. A 990 μL sample of the turnover was 
mixed with the internal standard (p-cresol, 10 μL, 20 mM). The organic metabolites were then 
extracted with ethyl acetate (400 μL) and separated by centrifugation (13000 rpm, 3 min), the organic 
layer was then removed and analysed via GC and GC-MS. 
The product formation rates were determined by analysing the samples with an internal standard (500 
μM) via GC and GC-MS. The ratio of total product area and internal standard was plotted against the 
concentrations to create the calibration curve which was used to determine the amount of metabolite 
generated in turnovers (Figure 2.3 (b)). To calculate the coupling efficiency (productive use of reducing 
equivalents), the concentration of the product formed in the turnover was divided by the 
concentration of NADH that was added. The coupling efficiency when multiplied by the NADH 
oxidation rate, gave the product formation rate (Eq 2.3). 
Product formation rate = Coupling efficiency x NADH oxidation rate      (Eq 2.3) 
  
2.8 Total Turnover Number (TTN) 
 
The total turnover number was determined with the best substrates to monitor the efficiency and 
activity of the enzyme over an extended period (2 h). ArR:Arx:CYP-enzyme was used in the 
concentration of 1:10:1. The CYP enzyme (0.1 μM) was combined with ArR (0.1 mM), Arx (1 μM), 2 
mM substrate and 4 mM NADH and oxygenated 50 mM buffer T pH 7.4 was used to bring the final 
volume up to 1.2 mL. The turnover mixture was then kept at room temperature for 2 hours before the 
extraction with 400 μL of ethyl acetate and analysed by GC and GC-MS. 
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Chapter-3 
Norisoprenoid oxidation by M82L-CYP10C1 compared to WT-




Ionone, damascone and their derivatives are known to be among the most highly valued fragrance 
constituents for their distinctive fine violet and rose scent [82, 83]. Besides their use in the perfume 
industry, these natural products are also useful as synthetic building blocks [84]. For example, -
ionone has been identified as a flavour ingredient of raspberries, carrots and black tea as well as a 
fragrant extract of plants including violet flower [85-87]. Structurally, ionones and damascones are 
C13 norisoprenoids which are differentiated by their butenone side chain and the position of the 
ketone functional group (Figure 3.1). In comparison ionols exhibit a similar structure with ionones and 
damascones, but differ in the functional group on the butenyl side chain which contains an alcohol 
functional group (Figure 3.1). The ,  and  isomers of ionones, damascones and ionols differ by the 
position of the double bond in the cyclohexenyl ring (Figure 3.1). 
 
Figure 3.1 Structures of norisoprenoid substrates used in this thesis. The butenone side chain of -
ionone and -damascone and the butenyl side chain of -ionol is highlighted in red, the alkene moiety 
inside each cyclohexane ring is highlighted in blue. 
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3.1.1 Site specific Mutation of CYP101C1 
 
Several of the CYP monooxygenases from Novosphingobium aromaticivorans including CYP101B1, 
CYP101C1, CYP101D1 and CYP101D2 are closely related to CYP101A1 (P450cam) from Pseudomonas 
putida. For example, CYP101C1 shares 36% sequence identity with CYP101D1, 38% with CYP101D2 
and 43% with CYP101A1 [78]. Whereas CYP101B1 is known to share 46% sequence identity with 
CYP101D2 and 44% with CYP101A1 and CYP101D1 [76]. The crystal structures of CYP101C1, CYP101D1 
and CYP101A1, along with a predicted homology modelled structure of the CYP101B1, shows that the 
Met82 residue of CYP101C1 spatially and structurally aligns with the His85 residue of CYP101B1 
(Figure 3.2) [9]. Moreover, this Met82 residue of CYP101C1 also aligns with the Tyr96 residue of 
CYP101A1 enzyme and Tyr98 residue of CYP101D1 enzyme (Figure 3.2) [78]. This tyrosine residue is 
also conserved in CYP101D2 enzyme. In these CYP101 enzymes the tyrosine forms a hydrogen bond 





Figure 3.2 a) Crystal structure of -ionone bound CYP101C1 (PDB ID: 3OFU) [78]. b) Modelled structure 
of CYP101B1 created using Swiss Model [88]. c) Crystal structure of camphor-bound CYP101A1 
(P450cam) (PDB ID: 3WRH). d) Crystal structure of CYP101D1 with bound camphor (PDB ID: 3LXI) [38]. 
The mutation site has been highlighted with a red circle.  
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Mutation of the tyrosine residue to remove the hydroxy group has been shown to enhance the affinity 
of both CYP101A1 and CYP101D2 against hydrophobic substrates [89, 90]. In addition, mutation of the 
histidine residue (His85) in CYP101B1 to a more hydrophobic phenylalanine is also reported to make 
the CYP101B1 more suitable for hydrophobic substrates including alkylbenzenes and naphthalene 
[88]. 
The reported crystal structure of -ionone bound CYP101C1, indicates that the active site is 
predominantly hydrophobic and the substrate forms Van der Waal contacts with the majority of 
residues in active site [78]. The substrate is oriented with the butenone chain pointing away from the 
heme where it interacts with the active side residues (Met82, Leu72, Ala73 and Leu78) (Figure 3.2) 
[88]. In addition, there is an interaction of the keto oxygen of -ionone with the sulfur atom of Met82 
residue. Therefore, it is hypothesised that replacing the Met82 with a more hydrophobic residue such 
as leucine, which is similar in size compared to methionine, may alter the affinity of CYP101C1 for 
norisoprenoid substrates like ionones and damascones. In this project, the M82L variant of CYP101C1 
enzyme was tested alongside the WT-CYP101C1 and WT-CYP101B1 enzyme with substrates like 




To assess the binding affinity of the WT-CYP101B1, WT-CYP101C1 and M82L-CYP101C1 enzymes, the 
substrates were first assessed by determining both the dissociation constant (Kd) and spin-state shifts 
(% HS). The dissociation constant measures how tightly the substrate binds to the enzyme and the 
spin-state shift induced by substrate binding provides a general indication of the ability of substrate 
to replace the water ligand bound to the heme iron, thereby determining accessibility to the active 
site pocket of the enzyme. Following this, in vitro turnovers were performed to analyse the NADH 
oxidation rate and product formation rate (PFR) (Section 2.7). These data were subsequently used to 
calculate the coupling efficiency, which is the percentage efficiency of NADH utilisation for the 
formation of products. Finally, experiments were performed to calculate the total turnover number 
(TTN) which is the number of turnovers catalysed per enzyme, for each substrate (Section 2.8). The 
spin-state shifts, NADH oxidation rate, PFR, coupling efficiencies, Kd and TTN for each enzyme 
substrate combinations are mentioned in Table 3.1. The enzyme-substrate combinations that 
exhibited the highest binding affinity and activity were then selected to scale up the product formation 
using a whole-cell oxidation system (Section 2.3).  
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3.2.1 Spin state shift and dissociation constant studies 
 
Based on available structural data, the affinity of the M82L-CYP101C1 enzyme with norisoprenoids 
was determined and compared with both WT-CYP101C1 and WT-CYP101B1. -Ionone induces a large 
type-I spin state shift (≥95% HS) and has a high affinity (Kd = 0.23 ± 0.1 μM) for WT-CYP101B1 [76]. 
This indicates that -ionone maybe, or is at least a close relative to the physiological substrate of 
CYP101B1 [76]. -Ionone, a structural analog of -ionone, was observed to have a similar spin state 
shift and dissociation constant of ≥95% HS and Kd = 0.26 ± 0.04 μM respectively with WT-CYP101B1 
[14, 19]. In the case of WT-CYP101C1, a small type-I spin-state shift of 20% HS (Figure 3.3 (a)) and a 
weaker dissociation constant of Kd = 63 ± 14 μM (Appendix, Figure A.3 (b)) was observed with -
ionone. The spin-state shift of -ionone was comparatively larger (40% HS, Figure 3.3 (b)), however, 
the dissociation constant was weaker (Kd = 117 ± 13 μM) (Appendix, A.3 (a)) [78]. With M82L-
CYP101C1 both, -ionone and -ionone displayed significantly smaller type-I spin state shift (20% HS 
with -ionone and 30% HS with -ionone, Figure 3.4). The dissociation constant was only calculated 
for M82L-CYP1201C1 with -ionone (Kd = 80 ± 7 μM) (Appendix, Figure A.5 (a)). Due to the small spin 
state shift, the dissociation constant was only calculated for substrates with spin state shift higher 
than 20% HS (refer to -ionol Kd in Appendix, Figure A.5 (c)). 










































Figure 3.3 Spin state shifts of WT CYP101C1 with a) -ionone and b) -ionone. 










































Figure 3.4 Spin state shifts of M82L-CYP101C1 with a) -ionone and b) -ionone. 
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To explore the effect of the position and function of the keto group on the butenone side chain, -
damascone and -ionol substrates were examined. WT-CYP101B1 shows a large type-I spin state shift 
of 80% HS on addition of -damascone and 90% HS with -ionol [76, 91]. Both substrates showed 
similar binding affinity (Kd = 8.3 ± 0.9 μM and 7.4 ± 0.2 μM respectively) with WT-CYP101B1, which 
was weaker compared to -ionone [91]. With WT-CYP101C1, -damascone exhibited a very small spin 
state shift (5% HS, Figure 3.5 (a)). -Ionol induced a larger spin-state shift of 35% HS (Figure 3.6 (a)).  











































Figure 3.5: Spin state shift for -damascone with a) WT-CYP101C1 and b) M82L-CYP101C1. 
The dissociation constant of -ionol with WT-CYP101C1 (Kd = 46 ± 3 μM, Figure 3.6 (b)), suggests that 
the substrate is binding somewhat tighter compared to -ionone (Kd = 63 ± 14 μM). The M82L-
CYP101C1 variant displayed a smaller spin-state shift with -damascone (< 5% HS; Figure 3.5 (b)) 
compared to -ionol (20% HS, Figure 3.7 (a)). The dissociation constant for -ionol (Kd = 34 ± 4 μM, 
Figure 3.7 (b)) also shows that the substrate is binding with higher affinity to the M82L mutant 
compared to WT-CYP101C1 enzyme (Table 3.1). In summary, the magnitude of the spin state shift of 
-substituted substrates trends were as follows: -ionol > -ionone > -damascone, with both M82L-
CYP101C1 and WT-CYP101C1. 






















































Figure 3.6 (a) spin state shift of -ionol with WT-CYP101C1, (b) dissociation constant analyses of -
ionol with WT-CYP101C1. 
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(b)  
Figure 3.7 (a) Spin state shift of -ionol with M82L-CYP101C1. (b) Dissociation constant analyses of -
ionol with M82L-CYP101C1. 
The substrate -ionol differs from -ionones by replacing the carbonyl group with an alcohol 
functional group (Figure 3.1). -Ionol has been reported to induce a large type-I spin-state shift of 70% 
HS when added to the WT-CYP101B1 enzyme [91]. This is lower than the spin-state shift of -ionone 
and -damascone with WT-CYP101B1 (Table 3.1). -Ionol binds weakly to WT-CYP101B1 compared 
to -ionone (40-fold) and -damascone (3-fold) (Table 3.1). In the case of WT-CYP101C1, -ionol 
induces a spin-state shift of 25% HS, which is smaller than that induced by -ionone (40% HS) and 
greater than -damascone (< 5% HS) (Table 3.1). -Ionol is also observed to bind lightly with WT-
CYP101C1 than with WT-CYP101B1 (Table 3.1). Whereas, -ionol binds with higher affinity to WT-
CYP101C1 compared to -ionone (Table 3.1). -Ionol induced a spin state shift of 20% HS with M82L-
CYP101C1 enzyme (Table 3.1) which is smaller in comparison to -ionone but higher than -
damascone.  











































Figure 3.8: Spin state shift for -ionol with a) WT-CYP101C1 and b) M82L-CYP101C1. 
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Both -damascone and -damascone, are reported to induce a lower spin state shift of 80% HS and 
65% HS respectively with CYP101B1 in comparison to -ionone [91, 92]. The -damascone substrate 
binds to CYP101B1 (Kd = 3.7 ± 0.3 μM) less tightly than -damascone (Kd = 0.9 ± 0.1 μM) and -ionone 
(Table 3.1). Both these substrates display a minimal spin state shift when screened with WT-CYP101C1 
(< 5% HS with -damascone and 10% HS with -damascone; Figure 3.9). This was lower than the spin-
state shift induced by -ionone (30% HS) and -ionone (40% HS) on WT-CYP101C1 (Table 3.1). The 
M82L-CYP101C1 enzyme also had a similar display of spin state shifts on addition of these substrates 
(5% HS with -damascone and 10% HS with -damascone; Figure 3.10).  











































Figure 3.9: (a) Spin state shift of -damascone with WT-CYP101C1. (b) Spin state of -damascone 
with WT-CYP101C1.  












































Figure 3.10: (a) Spin state shift of -damascone with M82L-CYP101C1. (b) Spin state of -damascone 
with M82L-CYP101C1.  
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Table 3.1: Substrate binding and in vitro turnover data for WT-CYP101B1, WT-CYP101C1 and M82L-
CYP101C1 variant with various norisoprenoid substrates. 
Enzyme/ 
Substrate 
NADH PFR C % HS % Kd (µM) TTN 
CYP101B1 
α-Ionone 
1380 ± 140 660 ± 60 48 95 0.26 ± 0.04 8660 
CYP101C1 
α-Ionone 
710 ± 5 510 ± 40 74 40 117 ± 13 4000 
M82L-CYP101C1 
α-Ionone 
810 ± 40 790 ± 20 97 30 80 ± 7 3140 
CYP101B1 
β-Ionone[91] 
1600 ± 100 1010 ± 60 63 95 0.23 ± 0.1 5240 
CYP101C1 
β-Ionone 
1600 ± 10 840 ± 80 51 30 63 ± 14 3000 
M82L-CYP101C1 
β-Ionone 
900 ± 20 500 ± 50 56 20 - 1600 
CYP101B1 
α-damascone[92] 
890 ± 10 460 ± 33 52 80 3.7 ± 0.3 2150 
CYP101C1 
α-damascone 
990 ± 10 520 ± 70 52 < 5 - 2070 
M82L-CYP101C1 
α-damascone 
900 ± 60 560 ± 60 62 5 - 940 
CYP101B1 
β-damascone[91] 
930 ± 13 560 ± 12 60 80 8.3 ± 0.9 7700 
CYP101C1 
β-damascone 
1220 ± 40 860 ± 100 70 10 - 850 
M82L-CYP101C1 
β-damascone 
1080 ± 85 665 ± 25 63 < 5 - 690 
CYP101B1 
δ-damascone[92] 
705 ± 32 420 ± 35 59 60 0.9 ± 0.1 1570 
CYP101C1 
δ-damascone 
1600 ± 20 1040 ± 40 63 10 - 2080 
M82L-CYP101C1 
δ-damascone 
1010 ± 30 680 ± 10 67 5 - 10 - 1540 
CYP101B1 
α-ionol[91] 
1030 ± 50 770 ± 76 75 70 11.4 ± 0.5 1400 
 CYP101C1 
α-ionol 
870 ± 40 590 ± 30 68 25 40 ± 4 2800 
M82L-CYP101C1 
α-ionol 
475 ± 60 250 ± 50 53 20 - 700 
CYP101B1 
β-Ionol[91] 
1030 ± 55 670 ± 84 65 90 7.4 ± 0.2 1200 
CYP101C1 
β-Ionol 
2020 ± 100 1130 ± 30 56 35 46 ± 3 2600 
M82L-CYP101C1 
β-Ionol 
1080 ± 80 530 ± 80 48 20 34 ± 4 1000 
 
NADH is the NADH oxidation rate, PFR is the product formation rate, C is the coupling efficiency, HS% 
is the spin state shift, Kd is the dissociation constant and TTN is the total turnover number. Data 
reported from previous studies is in black and included for comparison with reference, data collected 
during this thesis is in red. Rates are reported as mean ± S.D. (n ≥ 3) and given in nmol per nmol CYP 
per min. 
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3.2.2 In vitro turnover studies of norisoprenoids. 
 
The initial substrate binding screening (spin-state shift) with M82L-CYP101C1 enzyme showed little to 
no significant improvement for any of the tested substrates compared to the WT-CYP101C1 enzyme 
(Table 3.1). This suggests that the M82L mutation of the CYP101C1 enzyme did not enhance the 
substrate binding. To further test this hypothesis, in vitro experiments were performed with the M82L 
mutant of CYP101C1 along with WT-CYP101C1 and WT-CYP101B1 enzymes (Section 2.7). The product 
formation rate and selectivity were determined using GC and GC-MS analysis. The NADH oxidation 
rate and product formation rate were used to calculate the coupling efficiency. The reaction was 
scaled up to increase the quantity of metabolite produced using whole-cell turnover to characterise 
the obtained products (Section 2.3).  
WT-CYP101B1 is reported to oxidise -ionone with a high NADH oxidation rate of 1600 
nmol.(nmol.P450)-1.min-1 (henceforth abbreviated as min-1) [76]. The reported product formation rate 
is 1010 ± 60 min-1 and coupling efficiency is 63% (Table 3.1) [19, 76, 89]. This shows that the enzyme 
catalyses the oxidation of -ionone with good efficiency. It supports 5240 turnovers (TTN), which is 
the number of moles of product per mole of P450 [91]. With WT-CYP101C1, despite a significantly 
smaller spin state shift, -ionone was oxidised with a similar NADH oxidation rate (1600 ± 10 min-1). 
The product formation rate (840 ± 80 min-1) and coupling efficiency (51%) were slightly reduced than 
that with the CYP101B1. Also, the TTN with WT-CYP101C1 was reduced (3000) almost to half than that 
with WT-CYP101B1 enzyme (5240) [19, 38]. M82L-CYP101C1 on the other hand, oxidised -ionone 
with a slower NADH oxidation rate (900 ± 20 min-1) and product formation rate (500 ± 50 min-1). The 
coupling efficiency (56%) was similar, whereas, the TTN (1600) was reduced again by half, compared 
to WT-CYP101C1 (Table 3.1). Overall, in comparison to WT-CYP101B1 both the WT-CYP101C1 and 
M82L-CYP101C1 enzymes generated less yield of products and overall could not oxidise -ionone as 
efficiently. 
 
Figure 3.11: In vitro oxidation of -ionone with WT-CYP101B1, WT-CYP101C1 and M82L-CYP101C1. 
The product distribution of in vitro oxidation of -ionone with the M82L mutant variant, as observed 
by the GC analysis shows similar product selectivity to WT-CYP101C1 enzyme. The WT-CYP101C1 
enzyme is observed to favour the 4-hydroxy metabolite (tR = 13.87 min) as the major product (Figure 
3.11, Figure 3.12). This distribution is opposite to the selectivity of WT-CYP101B1, that favours the 3-
hydroxy product (tR = 15.03 min) (Figure 3.11, Figure 3.12). Both the products were identified by 
matching the NMR spectra and MS data with those previously reported [76]. A small peak was 
observed by the GCMS analysis of in vitro turnover with M82L-CYP101C1. This peak was not visible in 
GC (Figure 3.11, Figure 3.12). This product was yielded by whole-cell oxidation system and identified 
as anti-3,4-dihydroxy--ionone by NMR analysis (Figure 3.13). Further discussion on the assignment 
of the stereochemistry of this product has been explained in Appendix-A, Figure A.11. 





Figure 3.12: GC analysis of the in vitro turnover of WT-CYP101B1 (black) with -ionone in comparison 
to WT-CYP101C1 (red) and M82L-CYP101C1 (blue). The chromatograms have been offset along the x 
and y axes for clarity. Internal standard (†), impurity from GC (*). The peak at tR = 5.22 min and 7.51 
min were also present in the substrate. 
 
Figure 3.13: 1H NMR of anti-3,4-dihydroxy--ionone in CDCl3. Impurity / OH (*). Further data is 
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WT-CYP101C1 oxidises -damascone with high activity, as evident by a NADH oxidation rate of 1220 
± 40 min-1 and a product formation rate of 860 ± 100 min-1 (Table 3.1). Both the NADH oxidation rate 
and the product formation rate were also slightly lower, 1080 ± 85 min-1 and 665 ± 25 min-1 
respectively, when screened with M82L-CYP101C1. The coupling efficiency of -damascone with WT-
CYP101C1 (70%) was higher compared to M82L-CYP101C1 (63%) and both were greater compared to 
that of the WT-CYP101B1. Interestingly, the TTN of -damascone with WT-CYP101B1 (7700) was ten-
fold higher than with WT-CYP101C1 (850) and M82L-CYP101C1 (690). This could occur if WT-CYP101B1 
stayed catalytically active for longer period of time than the other enzymes or if any of the products 
formed with -damascone from the other enzymes are inhibitory in nature.  
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Figure 3.14: (a) In vitro oxidation of -damascone with WT-CYP101B1, WT-CYP101C1 and M82L-
CYP101C1. (b) GC-FID analysis of the in vitro turnover of WT-CYP101B1 (black) with -damascone in 
comparison to WT-CYP101C1 (red) and M82L-CYP101C1 (blue). The chromatograms have been offset 
along the x and y axes for clarity. Internal standard (†), impurity from GC (*). The impurity from 
substrate is marked (#). The minor peak at tR = 6.75 min is an impurity from -ionol and at 12.05 min 
is from -damascone, which are present in substrate. 
The product distribution of -damascone oxidation by WT-CYP101C1 and M82L-CYP101C1 were 
altered in comparison to WT-CYP101B1. The metabolites were generated in a higher quantity through 
whole-cell turnovers and separated by HPLC. The products were analysed by NMR (Figure 3.14) and 
compared to published literature [76]. Both WT-CYP101C1 and M82L-CYP101C1 yielded the 4-hydroxy 
metabolite (tR = 11.9 min) as the major product (81%, 84%) and 3-hydroxy (tR = 12.88 min) as the 
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secondary metabolite (19%, 16%) as previously reported (Figure 3.14) [76]. The other minor product 
(tR = 13.05 min; Figure 3.14(b)) is characterised as anti-3,4-dihydroxy--damascone by GCMS.  
 
Figure 3.15: 1H NMR of 4-hydroxy-β-damascone in CDCl3. Impurity (*), H2O (#). (†) The signal for H2a 
is present as a multiplet signal which is partly visible at 1.7 ppm and partly hidden behind the signal 
for H10 at 1.66 ppm. Further data provided in Appendix-A, Figure A.14. 
The norisoprenoid -ionol, in which the carboxyl group on the butenone side chain of -ionone is 
replaced by an alcohol functional group, was oxidised with a product formation rate of 670 ± 84 min-
1 by WT-CYP101B1. The NADH oxidation rate was 1030 ± 55 min-1 and the coupling efficiency was 65%. 
The TTN was reduced 4-fold (1200) in comparison to -ionone [91]. WT-CYP101C1 oxidised -ionol 
with the fastest NADH oxidation rate (2020 ± 100 min-1) and product formation rate (1130 ± 30 min-1) 
compared to any other substrate. This rate of the enzyme turnover was reduced by half (1080 ± 80 
min-1 and 530 ± 80 min-1 respectively) when -ionol was oxidised with M82L-CYP101C1. The coupling 
efficiency (56%) was lower with WT-CYP101C1 enzyme in comparison with WT-CYP101B1 (65%). The 
TTN (2600) of -ionol oxidation was highest with WT-CYP101C1, amongst the three enzymes. With 
M82L-CYP101C1, the coupling efficiency (48%) and the TTN (1000) was lower than both WT enzymes.  
-Ionol yielded a mixture of 4-hydroxy--ionol (49%, tR = 13.74 min) and 3-hydroxy--ionol (39%, tR = 
14.60 min) as the major products (Figure 3.16) which was identified by comparison with previously 
reported data with CYP101B1 [76, 91]. This selectivity of -Ionol WT-CYP101B1 contrasted with that 
of -ionone with WT-CYP101B1 (Figure 3.12). The 4-hydroxy metabolite was generated as the major 
product with both the WT-CYP101C1 (79%) and M82L-CYP101C1 (66%). The 3-hydroxy metabolite was 
generated in a smaller quantity with both the WT-CYP101C1 (12%) and M82L-CYP101C1 (23%) 
enzymes (Figure 3.16). A minor product (tR = 14.97 min) is observed with all three enzymes and has 
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Figure 3.16: GC-FID analysis of the in vitro turnover of WT-CYP101B1 (black) with -ionol in 
comparison to WT-CYP101C1 (red) and M82L-CYP101C1 (blue). The chromatograms have been offset 
along the x and y axes for clarity. Internal standard (†), impurity from substrate is marked as (*). The 
peak at tR = 12.55 min and 13.17 min are oxidation of -ionone impurity present in substrate. The 
peak at tR = 12.75 min is the oxidation of -damascone impurity present in substrate. The peak at tR = 
5.22 min, 13.74 min and 14.37 min are from -ionone and its oxidation. The product at 14.97 is not 
yet characterised and labelled as (unknown). 
To understand the importance of the carbonyl and alcohol groups, the data for -ionone was 
compared to that seen for -ionol (Figure 3.1). -Ionol differs from -ionone only by the functional 
group on the butenyl side chain (Figure 3.1). With WT-CYP101B1, both -ionone and -ionol yielded 
fast NADH oxidation rates of 1380 ± 140 min-1 and 1030 ± 50 min-1, respectively. The product formation 
rates of both substrates were also similar (660 ± 60 min-1 and 770 ± 76 min-1, respectively). However, 
the coupling efficiency with -ionol (75%) was higher than for -ionone (48%). Among all the 
substrates tested, -ionone resulted in the highest TTN (8660) with WT-CYP101B1 (Table 3.1). In the 
case of oxidation by WT-CYP101C1, -ionol exhibits higher NADH oxidation rate (870 ± 40 min-1) and 
product formation rate (590 ± 30 min-1), in comparison to -ionone that shows a NADH oxidation rate 
of 710 ± 5 min-1 and product formation rate of 510 ± 40 min-1 (Table 3.1). Whereas, with M82L-
CYP101C1, the NADH oxidation rate and product formation rate of -ionol was reduced to almost half 
(475 ± 60 min-1 and 250 ± 50 min-1) in comparison to its oxidation by WT-CYP101C1. Interestingly, in 
the case of -ionone both the NADH oxidation rate (810 ± 40 min-1) and the product formation rate 
(790 ± 20 min-1) were increased in comparison to WT-CYP101C1 and these rates were much higher 
than -ionol. The coupling efficiency (74%) and TTN (4000) were higher for -ionone with WT-
CYP101C1, in comparison to -ionol (Coupling efficiency = 68%, TTN = 2800) (Table 3.1). Whereas, -
ionone oxidation by M82L-CYP101C1 was supported by a TTN of 3140 and coupling efficiency of 97%, 
which was much higher than the TTN (700) and coupling efficiency (53%) of -ionol oxidation by M82L-
CYP101C1.  





















































































































Figure 3.17: (a) In vitro oxidation of -ionone with WT-CYP101B1, WT-CYP101C1 and M82L-CYP101C1. 
(b) In vitro oxidation of -ionol with WT-CYP101B1, WT-CYP101C1 and M82L-CYP101C1. (c) GC-FID 
analysis of the in vitro turnover of WT-CYP101B1 (black) with -ionone in comparison to WT-CYP101C1 
(red) and M82L-CYP101C1 (blue).  (d) GC-FID analysis of the in vitro turnover of WT-CYP101B1 (black) 
with -ionol in comparison to WT-CYP101C1 (red) and M82L-CYP101C1 (blue). Both the substrates 
have trace amount of -Ionone and its oxidation product, labelled as (#). The chromatograms have 
been offset along the x and y axes for clarity. Internal standard (†), impurity from GC (*). In (d), the 
peak at tR = 7.89 min is an impurity from -damascone. The peak at tR = 12.55 min and 13.17 min are 
oxidation of -ionone impurity present in substrate. The peak at tR = 12.75 min is the oxidation of -
damascone impurity present in substrate. 
GC analysis of in vitro oxidation of -ionone revealed the formation of two products (Figure 3.17 (a)) 
which were characterised by NMR analysis, this data was in agreement with previously published data 
[76]. Intriguingly, both the products were found to be oxidised at C3 position but with different 
configurational isomers (Figure 3.17 (a)). These cis / trans metabolites eluted closely on a DB-wax 
column using GC (Figure 3.18 (c)). However, these isomers were separated for characterisation using 
a normal phase HPLC column (Figure 3.18 (a)). The oxidation of -ionone by WT-CYP101B1 generated 
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trans-3-hydroxy--ionone (tR = 13.4 min) as the major product (72%) (Figure 3.18 (b)), whereas both 
WT-CYP101C1 and M82L-CYP101C1 enzymes favoured the cis-3-hydroxy--ionone (tR = 13.47 min, 
68% with WT-CYP101C1 and 77% with M82L-CYP101C1; Figure 3.17 (a)). A minor product was 
observed at tR = 13.90 min with -ionone oxidation by WT-CYP101B1 and M82L-CYP101C1. The mass 
spectra of this metabolite matches with the reported mass spectra of 3-oxo--ionone (Figure A.20). 
In the case of -Ionol, WT-CYP101B1 favoured the cis isomer (tR = 13.65 min, 52%) whereas the M82L-
CYP101C1 and WT-CYP101C1 both favoured the trans isomer (tR = 13.45 min, 68%, 66%; Figure 3.17 
(b)). A minor product at tR = 13.85 min was characterised as 3-oxo--ionol by GCMS analysis (Figure 
A.25). 





















Figure 3.18: (a) HPLC analysis showing the separation of cis-3-hydroxy--ionone and trans-3-hydroxy-
-ionone metabolite (b) 1H NMR of trans-3-hydroxy-α-ionone in CDCl3. Impurity / OH (*). H2O (#), The 
proton signal for H6 is shown as a multiplet, which is partly seen at 2.29 ppm and partly hidden behind 
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To assess the role of alkene moiety inside the cyclohexyl ring, -damascone and -damascone (Figure 
3.1) were screened with all three enzymes. Both -damascone and -damascone were oxidised by 
WT-CYP101B1 with NADH oxidation rates of 890 ± 10 min-1 and 705 ± 32 min-1 respectively [92]. The 
product formation rates (460 ± 33 min-1, 420 ± 35 min-1) and coupling efficiencies (52%, 59%) were 
similar for both substrates with WT-CYP101B1 [92]. This shows that changing the alkene position did 
not alter the rate of product formation or coupling efficiency significantly with WT-CYP101B1. WT-
CYP101C1 oxidised both the substrates with an NADH oxidation rates of 990 ± 11 min-1 and product 
formation rate of 520 ± 70 min-1 for -damascone and 1600 ± 20 min-1 and 1040 ± 40 min-1 for -
damascone. The NADH oxidation rate of -damascone with WT-CYP101C1 is similar to the oxidation 
of -ionone by the same enzyme. Whereas, the product formation rate is higher for -damascone, this 
suggests that -damascone is more efficiently oxidised than -ionone by WT-CYP101C1. With M82L-
CYP101C1, the NADH oxidation rates of both -damascone and -damascone were decreased to 900 
± 60 min-1 and 1010 ± 30 min-1 respectively. The product formation rate was increased to 560 ± 60 min-
1 for the oxidation of -damascone by M82L-CYP101C1. Whereas, the same enzyme decreased the 
product formation rate to 680 ± 10 min-1 for -damascone. The coupling efficiency was higher for -
damascone in comparison to -damascone with all three enzymes (Table 3.1). TTN of -damascone 
(2070) was similar in comparison to -damascone (2080) with WT-CYP101C1. With M82L-CYP101C1 
the TTN was much higher for -damascone (1540) than -damascone (940). 
Similar to the -ionone and -ionol reported previously, -damascone is also oxidised at C3 position 
by all three enzymes. The GC analysis of in vitro turnovers of -damascone shows that both WT-
CYP101C1 and M82L-CYP101C1, generated the cis-3-hydroxy--damascone as a major product (tR = 
11.31 min, 84% with WT-CYP101C1 and 80% with M82L-CYP101C1) (Figure 3.19 (a)). Interestingly, the 
turnovers with WT-CYP101B1 also generated the cis-3-hydroxy metabolite in excess (61%, Figure 3.19 
(a)). This is in contrast to its behaviour with -ionone, where the trans isomer is the major metabolite 
(Figure 3.17 (a)). Both the metabolites were generated in larger quantity by whole-cell oxidation 
system and characterised by comparing the NMR spectra with the reported literature data [92]. A 
third product was also generated by all three of the enzymes (tR = 11.67 min, ≤ 4%; Figure 3.19 (a)), 
which was not generated in high enough amount to be characterised by NMR analysis. By GC-MS 
analysis we observed that it has a mass indicating it arises from further oxidation of an alcohol product 
to a ketone (tR = 13.38 min, 206 AMU; Appendix-A, Figure A.22). In the case of -damascone, both WT-
CYP101C1 enzyme and M82L-CYP101C1 formed the same major product (Figure 3.19 (b)), which was 
characterised by NMR analysis as 3,4-epoxy--damascone (tR = 8.01 min, Figure 3. 20). A minor product 
which was characterised by NMR analysis as 2-hydroxy--damascone (tR = 11.44 min, Figure 3.21) was 
only generated with M82L-CYP101C1 and WT-CYP101C1 (Figure 3.19 (b, d)). WT-CYP101B1 generated 
a single product with -damascone. -Damascone is the only substrate that yielded a 2-hydroxy 
metabolite which led us to believe that the position of alkene moiety inside the cyclohexyl ring does 
play a significant role in defining the selectivity of oxidation. 
  


































































































Figure 3.19:(a) In vitro oxidation of -damascone with WT-CYP101B1, WT-CYP101C1 and M82L-
CYP101C1. (b) In vitro oxidation of -damascone with WT-CYP101B1, WT-CYP101C1 and M82L-
CYP101C1. (c) GC-FID analysis of the in vitro turnover of WT-CYP101B1 (black) with -damascone in 
comparison to WT-CYP101C1 (red) and M82L-CYP101C1 (blue). (d) GC-FID analysis of the in vitro 
turnover of WT-CYP101B1 (black) with -damascone in comparison to WT-CYP101C1 (red) and M82L-
CYP101C1 (blue). The chromatograms have been offset along the x and y axes for clarity. Internal 
standard (†), impurity from GC (*). In (c), the peak at tR = 7.89 min is an impurity of -damascone. The 
peak at tR = 10.65 min is an impurity from -ionone. The peak at tR = 11.65 min is present in the 
turnover of -damascone, -ionone and the substrate as well. In (d), the peak at tR = 11.69 min is an  





Figure 3.20: (a) (a) 1H NMR of 3,4-epoxy--damascone in CDCl3. (b): 13C NMR of 3,4-epoxy--
































Figure 3.21: (a) 1H NMR of 2-hydroxy--damascone in CDCl3. (b): 13C NMR of 2-hydroxy--damascone 




























Norisoprenoids can be derived from the breakdown of carotenoids and carotenoid dioxygenase 
(13,14-dioxygenase), which are known to be present in N. aromaticivorans [93, 94]. These 
norisoprenoids have a common cyclohexyl ring with an alkene and a butene side chain with ketone as 
a functional group for ionones and damascones whereas, ionols have an alcohol functional group. 
The crystal structure of CYP101C1 bound to -ionone has revealed that the active site residues of 
CYP101C1 are significantly different from those of camphor oxidising CYP101A1, CYP101D1 and 
CYP101D2 (Figure 3.2). For example, Met82 aligns with Tyr96 (CYP101A1 numbering given), Leu87 
with Thr101 and Asn383 with Ile395. Such differences are bound to alter the substrate profile for 
CYP101C1. The physiological substrate of both CYP101C1 and CYP101B1 enzymes are yet to be 
confirmed, however CYP101B1 has been studied to oxidise norisoprenoids (ionones, damascones) 
with high efficiency and high binding affinity, these substrates induce large type-I spin state shifts with 
CYP101B1. Whereas, the same norisoprenoid substrates show a weak binding (30-117 μM) and induce 
a small spin state shift of ≤ 40% with CYP101C1. 
The functional data (section 3.3) aligns with the crystallographic data that shows that the C3 and C4 
atoms are held closest to the heme iron and thus more favoured for oxidation. In the case of -ionone 
and -damascone, the majority of product was obtained by C4 hydroxylation with both the M82L 
mutant and WT-CYP101C1 indicating that the enzymes prefer allylic C4 position for hydroxylation 
which is altered in the case of CYP101B1, that prefers the allylic C3 position (Figure 3.11, Figure 
3.14(a)). This shows that altering the position of the keto group on butene side chain does not 
significantly affect the oxidation or the product distribution for WT-CYP101B1. But when the keto 
group itself is substituted by an alcohol group (-ionol), both CYP101C1 and its M82L variant mutant 
enzyme yielded C3 hydroxylation in majority with all three enzymes (Figure 3.22). This suggests that 
on changing the keto group to alcohol, CYP101B1 still prefers oxidation at the C3 position but an 
interesting change is observed by both M82L-CYP101C1 mutant and WT-CYP101C1 enzyme that prefer 
the C3 position instead of C4 like the corresponding ionone and damascone.  
 
Figure 3.22: in vitro oxidation of -ionol with WT-CYP101B1, WT-CYP101C1 and M82L-CYP101C1. 
In terms of activity, the trend for tested norisoprenoid substrates with WT-CYP101B1 were as follow: 
-ionone > -ionone > -ionol > -ionol > -damascone > -damascone > -damascone. With WT-
CYP101C1 the trend follows: -ionol > -damascone > -ionone > -damascone > -damascone > -
ionol > -ionone. Whereas, the M82L-CYP101C1 shows a different trend: -damascone > -ionol > -
damascone > -ionone > -damascone > -ionone > -ionol.  
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On comparing the  substituted norisoprenoids of respective ionone, damascone and ionol with the 
results of  substituted norisoprenoids. We observed that the alkene moiety present inside the 
cyclohexyl ring of  substituted norisoprenoids helps the substrate to orient in a way that ensures the 
C3 carbon is present closest to the heme and hence oxidises the carbon exclusively at C3 as opposed 
to the  substituted equivalents. The major product generated during the oxidation of -ionone with 
CYP101B1 favours the trans configuration whereas the M82L-CYP101C1 and its wild type enzyme 
favours cis configuration. This product distribution is altered in the case of -damascone, where all 
three of the enzymes generate the cis-3-hydroxy--damascone. This suggests that by changing the 
position of keto group on the butenone side chain enables the enzyme to orient the substrate within 
active site of CYP101B1, in the same way that -damascone and -ionone is arranged in the active 
site of M82L-CYP101C1 and WT-CYP101C1 enzyme. In terms of oxidation behaviour -ionol replicates 
the -ionone by generating the cis-3-hydroxy--ionol in majority with CYP101B1 and the 
corresponding trans equivalent in majority with both M82L-CYP101C1 and WT-CYP101C1. 
To check our hypothesis, we tested the oxidation behaviour of -damascone, that differ simply by the 
position of the alkene moiety (between C3 and C4) inside the cyclohexyl ring with WT-CYP101C1, 
M82L-CYP101C1 and WT-CYP101B1. As expected, the M82L-CYP101C1 mutant and WT-CYP101C1 
enzyme both yielded the 3,4-epoxy- -damascone as the major product (Figure 3.19 (b, d). The 2-
hydroxy--damascone could arise because of the affinity of the enzyme for allylic hydrogen. On the 
other hand, the in vitro oxidation of -damascone with WT-CYP101B1 generated one single product 
of the 3,4-epoxy metabolite, that shows C2 is further away from the heme of WT-CYP101B1 than with 
WT-CYP101C1 enzyme. This suggests that the position of the carbonyl group on the butenone side 
chain and the alkene in the cyclohexyl ring plays a crucial role in orienting the substrate in the active 
site of WT-CYP101B1, WT-CYP101C1 and M82L-CYP101C1 for oxidation. 
In future, the enantio and stereoselectivity of hydroxylated metabolite can be observed by running 
the metabolites on a chiral column and getting a ROESY NMR. Also, the crystal structure of the 
substrates mentioned in this chapter with WT-CYP101B1 could provide more insight into the 
orientation of these substrates in active site. The whole cell turnovers could also be optimised to 
generate the minor products in a larger quantity for characterisation by NMR analysis.  
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Chapter-4 
Oxidation of cyclic ketone, amide or ester containing molecules by 




Terpenoids are a class of naturally occurring organic compounds that are derived from isoprene units. 
Terpenoid oxidation by natural and modified P450 enzymes is of high interest due to their biological 
properties and use as flavour and fragrance agents [74, 95]. For example, terpenoids contribute to the 
scent and fragrance profiles of eucalyptus, cinnamon, cloves and ginger [96]. Along with 
norisoprenoids, monoterpenoid acetates (which also possess a carbonyl group on a side chain) have 
been reported to be oxidised by CYP101B1 with high catalytic efficiency [91]. For example, fenchyl 
acetate was selectively oxidised by CYP101B1 to 5-exo-hydroxyfenchyl acetate with a product 
formation rate greater than 1000 min-1, exceeding that for norisoprenoids (Figure 4.1 (a)) [91]. 
Cycloalkanones and cycloalkyl esters are another class of compounds which are used in the 





Figure 4.1: (a) Fenchyl acetate oxidation by CYP101B1 [91]. (b) Structure of (+)-Sclareolide. 
Sesquiterpene lactones, which have structural similarity to norisoprenoids, have been shown to bind 
to CYP101B1 with moderate affinity and induce a large type-I spin state shift. For example, (+)-
Sclareolide (Figure 4.1(b)), a plant natural product containing a carbonyl functional group in a similar 
position relative to the methyl-substituted cyclohexane ring of norisoprenoids. This binds to CYP101B1 
with a Kd = 20 ± 4 μM and induces a spin-state shift of 50% [91]. 
Activation of the C-H bond of these compounds is a challenging task in the field of fine chemical 
synthesis [99-101]. For example, cyclohexanone and cyclohexanol, which are essential chemical 
intermediates for the synthesis of polyamides and plastics are synthesised using H2O2 hydroxylation 
and Au-Pd bimetallic catalysts [25, 102, 103]. An alternate and efficient approach to use biocatalysis 
instead of toxic chemical catalyst could be of high interest. Various bacterial and fungal species have 
been reported to oxidise the C-H bond of these cyclic compounds [86, 104]. 
The monooxygenase enzyme CYP101B1 and CYP101C1, from Novosphingobium aromaticivorans 
DSM12444, has been reported to oxidise norisoprenoids (Chapter-3) and other structurally  diverse 
classes of substrate [14, 19, 76, 91]. -ionone has been reported to be oxidised by CYP101B1 
preferentially at the C3 (80%) position whereas, CYP101C1 prefers to oxidise at the C4 (75%) position 
[38, 78]. Previously (Chapter-3), we have discussed the importance of the butenone side chain of -
ionone in binding the substrate in the active site of these enzymes. 
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It has been shown that the addition of a carbonyl group to larger ring structures improves the binding 
affinity of the substrate towards CYP101B1 and CYP101C1 [105, 106]. For example, cyclododecane 
binds to CYP101B1 with lower affinity (30% HS; Kd = 0.16 ± 0.03 μM) and generates a diol instead of a 
monohydroxy product (Figure 4.2). The monohydroxy is generated but not observed because it acts 
as a better substrate than cyclododecane (Figure 4.2). 
 
Figure 4.2: Cyclododecane oxidation by CYP101B1. 
However, cyclododecanone binds to CYP101B1 higher affinity (90% HS; 0.16 ± 0.03 μM) and high 
selectivity generating a single monohydroxy major product in high yield with both CYP101B1 and 
CYP101C1 enzyme (Figure 4.3) [105]. This suggests that the ketone moiety enables more favourable 
binding in the active site of these enzymes. CYP101B1 has been reported to oxidise cyclic ketones 
selectively at the position opposite to the keto group, whereas, CYP101C1 prefers the position next to 
the keto group (Figure 4.3) [106]. 
 
Figure 4.3: Cyclodedecanone oxidation by CYP101B1 and CYP101C1. 
CYP101B1 and CYP101C1 have also been demonstrated to oxidise cycloalkanes with an ester directing 
group more efficiently than their parent cycloalkanes [91]. The ester directing group is thought to 
resemble the butenone side chain of a norisoprenoid and helps to hold the substrate in a suitable 
orientation for efficient and selective oxidation [91]. For example, cyclododecyl acetate bound to 
CYP101B1 induces a spin state shift of almost completely high spin (95% HS) and binds to the enzyme 
with high affinity (Kd = 0.05 ± 0.01 μM) [105]. It was oxidised to generate 7-trans-cyclododecyl acetate 
with 74% selectivity (Figure 4.4) [105]. 
 
Figure 4.4: The oxidation of cyclododecyl acetate by CYP101B1. The remaining 16% of product yield 
was another hydroxy species, not generated in sufficient quantity for characterisation. 
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Keeping all this in mind, we selected a range of diverse substrates containing a carbonyl group or ester 






Figure 4.5: Substrates screened with CYP101B1 and CYP101C1 (except p-tolyl acetate, which was only 
screened with CYP101B1). Molecular weights are mentioned to indicate the range of molecular 
weights that could be accommodated by the enzyme. 
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Most of these substrates (Figure 4.5) are industrially useful. The two decalones (trans-1-decalone 
and 2-decalone) are used as fragrance agents. Muscone is considered a valuable compound and a 
primary contributor to the odour of musk. Homosalate is widely used as a chemical in sunscreens 




These substrates (Figure 4.5) were initially screened to access if they induce a spin-state shift when 
added to both CYP101B1 and CYP101C1. The spin-state shift induced by substrate binding gives an 
indication of the ability of substrate to replace the water ligand bound to the heme centre and hence 
if it fits in the active site pocket of the enzyme. Later, in vitro oxidation studies (section 2.7) were 
carried out for the substrates with both CYP101B1 and CYP101C1, the products were then analysed 
for product formation by GCMS. Amongst the substrates tested, those with a reasonable NADH 
oxidation rate were again screened for in vitro oxidation studies in triplicate and analysed again for 
product formation by GCMS. Finally, dissociation constant studies were performed for the best 
substrates (Figure 4.19). The best enzyme / substrate combination was then used to scale up the 
products formed using a whole-cell turnover system (Section 2.3). The obtained products were then 
separated or purified by flash chromatography on a silica column using a hexane / ethyl acetate 
stepwise gradient before characterisation (Section 2.3). 
 
4.2.1 Spin-state shift studies 
 
With CYP101B1 enzyme, the cyclic ketone substrates showed a significant type-I spin-state shift. For 
example, trans-1-decalone and 2-decalone both showed moderately high spin state shifts of 60% HS 
and 50% HS (Figure 4.6, Table 4.1). Muscone displayed a spin state shift of 45% HS (Figure 4.6, Table 
4.1) with CYP101B1. The spin state shift of 2-cyclohexylcyclohexanone was observed to be 55% (Table 
4.1). Other cycloketone derivatives such as trans-[4’-butyl-1,1’-bicyclohexyl]-4-one, 4-(trans-4-
propylcyclohexyl) cyclohexanone and 4-heptylcyclohexanone exhibits spin-state ranging from 15% HS 
to 30% HS (Table 4.1). Cyclic esters and lactones such as 8-oxaspiro[4.5]decane-7,9-dione, 
dihydroactinidiolide, octahydro-2H-chromen-2-one and undecanoic--lactone exhibited a low spin 
state shift ranging from (5-35%, Figure 4.6, Table 4.1). On the other hand, oxacyclotridecan-2-one, 
which is also a lactone, displayed a spin state shift of 70% HS with CYP101B1 (Figure 4.6, Table 4.1). 
Homosalate, that contains an ester group exhibits a spin-state shift of 15% HS (Table 4.1). 
Parthenolide, a sesquiterpene lactone that shifts the spin state by 40% HS (Table 4.1). Icaridin induces 
a small spin-state shift of 20% HS (Table 4.1). N-(Ter-butyl) decahydroisoquinone-3-carboxamide, 
where the decahydroisoquinoline ring is attached to a t-butyl group via an amide linkage showed a 
spin-state shift of 5% HS (Figure 4.6, Table 4.1). p-Tolyl acetate induced the highest spin-state shift of 
75% HS (Table 4.1). 
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Figure 4.6: Spin state shift graphs of selected substrate with CYP101B1. Further spin state spectra of 
the substrates with CYP101B1 are shown in Appendix-B (Figure B.1) 
Table 4.1: Spin state data of selected substrate with CYP101B1. 
Substrate %HSa Substrate %HSa 
p-tolyl acetate 75  Undecanoic--lactone 30 
Cyclopentadecanone 75 Dihydroactinidiolide 25 
Oxacyclotridecan-2-one 70 Octahydro-2H-chromen-2-one 25 
trans-1-Decalone 60 Icaridin 20 
2-Cyclohexylcyclohexanone 55 4-Heptylcyclohexanone 20 
2-Decalone 50 trans-[4’-Butyl-1,1’-bicyclohexyl]-4-one 15 
Muscone 45 Homosalate 15 






a the spin-state shift induced by substrate binding is given by the percentage of high spin heme 
(%HS). 
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With CYP101C1, all the substrates (Figure 4.5) exhibits a spin state shift in range of 0% HS to 10% HS 
(Table 4.2). 













































































































Figure 4.7: Spin-state shift graphs of selected substrates with CYP101C1. Further spin state spectra of 
the substrates with CYP101C1 are shown in Appendix-B (Figure B.3) 
Table 4.2: Spin-state shift data of selected substrate with CYP101C1 
Substrate %HSa Substrate %HSa 
p-Tolyl acetate 0 Undecanoic--lactone 10 
Cyclopentadecanone 10 Dihydroactinidiolide 0 
Oxacyclotridecan-2-one ≤ 5 Octahydro-2H-chromen-2-one 0 
trans-1-Decalone 0 Icaridin 0 
2-Cyclohexylcyclohexanone 0 4-Heptylcyclohexanone 10 
2-Decalone 0 trans-[4’-Butyl-1,1’-bicyclohexyl]-4-one 10 
Muscone 10 Homosalate 10 






athe spin-state shift induced by substrate binding is given by the percentage of high spin heme 
(%HS).  
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4.2.2 In vitro oxidation turnover studies 
 
In vitro oxidation studies were carried out for all the selected substrates (Figure 4.5) with both 
CYP101B1 and CYP101C1. These substrates were evaluated for the rate at which they consume NADH, 
which could either lead to generation of product or uncoupling side reactions (Chapter-1). The 
oxidation products were analysed by GCMS based on the change in mass (Δm/z) compared to the 
substrate. 
The substrate trans-1-decalone when oxidised by CYP101B1 exhibits an NADH oxidation rate of ~265 
min-1 (Figure 4.8 (a)). The GCMS analysis of this turnover reaction solution reveals three separate 
products at tR = 9.06, 9.27, 9.4 min (Figure 4.8 (c)). Mass spectra of all the three products indicates 
that they are mono-hydroxylated products with a mass of m/z = 168 AMU (Δm/z = +16 AMU) (Figure 
B.6). The substrate 2-decalone was supplied as a mixture of its cis and trans isomers. The addition of 
substrate caused an NADH oxidation rate of ~470 min-1 (Figure 4.8 (b)). This substrate generated four 
different metabolites at tR = 8.40, 9.53, 9.86 and 10.02 min (Figure 4.8 (d)) which on analysis showed 
a mass of m/z = 168.05 AMU (Δm/z = +16 AMU) (Figure B.7). This indicates that they were all 
monohydroxylated products.  





















































































































Figure 4.8: UV-Vis plots of in vitro turnover of (a) trans-1-decalone and (b) 2-decalone at 340 nm. 
GCMS analysis of the in vitro turnover (zoomed in) of (c) trans-1-decalone and (d) 2-decalone with 
CYP101B1 (black) with substrate control (red). The impurities are marked as (*), also present in 
substrate control. 
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Cyclopentadecanone was oxidised by CYP101B1 with a NADH oxidation rate of ~100 min-1 (Figure B.2). 
The GCMS analysis exhibits the generation of two metabolites (Figure 4.9). The metabolite at tR = 14.65 
min exhibits a mass of, m/z = 238 AMU (Δm/z = +14 AMU), the change in mass by two units compared 
to the oxidation product that would indicate an oxygen has been added to the compound with an 
additional abstraction of hydrogen to generate a ketone further oxidation product. The second 
metabolite at tR = 15.08 min (Figure 4.9) has a mass of m/z = 240.25 AMU (Δm/z = +16 AMU) (Figure 
B.8). This suggests that it is a monooxygenase product.  






























Figure 4.9: GCMS analysis of the in vitro turnover (zoomed in) of cyclopentadecanone (m/z = 224 AMU) 
by CYP101B1 (black) with substrate control (red). The products are identified at tR = 14.65 min and tR 
= 15.08 min. Further data given in Appendix-B, Figure B.8. 
CYP101B1 mediated in vitro oxidation of oxacyclotridecan-2-one caused an NADH oxidation rate of 
~360 min-1 (Figure B.2). The GCMS analysis of this turnover shows that three different metabolites 
were generated at tR = 11.99 min, 12.1 min and 13.18 min (Figure 4.10). All three metabolites showed 
mass of m/z = 214.1 AMU (Δm/z = +16 AMU) suggesting all three of them may be a monooxygenase 
product (Figure B.10). 





























Figure 4.10: GCMS analysis of the in vitro turnover (zoomed in) of oxacyclotridecan-2-one by 
CYP101B1 (black) with substrate control (red). Products at tR = 11.99 and 13.18 min. The metabolite 
marked as (*) is the oxidation of the impurity present in substrate. Further data given in Appendix-B, 
Figure B.10. 
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GCMS analysis of in vitro oxidation of p-tolyl acetate by CYP101B1 showed production of two 
metabolites. The substrate was observed at tR = 4.25 min with a mass of (m/z = 150.05 AMU) (Figure 
4.11 (a)). The metabolite at tR = 8.0 min has a mass of (m/z = 166.05 AMU, Δm/z = +16) (Figure 4.12, 
which was later characterised as 7-hydroxy-p-tolyl acetate by NMR analysis (Figure 4.25). The peak at 
tR = 6.58 min corresponds to the mass of (m/z = 124 AMU, Δm/z = -26 AMU) suggests that it could be 
4-hydroxybenzyl alcohol generated from the hydroxylation of p-cresol (m/z = 108.05 AMU) (Figure 
4.11). This could also be generated from the hydrolysis of the ester group in the 7-hydroxy-p-tolyl 
acetate product. This was confirmed by comparing the mass spec data to the reported data in NIST 
chemistry WebBook, SRD 69.  





























































Figure 4.11: (a) GCMS analysis of the in vitro turnover of p-tolyl acetate by CYP101B1 (black) with 
substrate control (red). Products observed at tR = 6.58, 8.0 min. The impurity from substrate and its 
oxidation product is marked as (*), Internal standard is marked as (I.S.). 
MS analysis of p-tolyl acetate oxidation product (4-hydroxybenzyl alcohol) at tR = 6.58 min (m/z = 
124.05 AMU, Δm/z = + 16 AMU) (NIST MS number: 231451). 
  
MS analysis of p-tolyl acetate oxidation product (7-hydroxy-p-tolyl acetate) at tR = 8.00 min (m/z = 
166.050 AMU, Δm/z = + 16 AMU)  
  
Figure 4.11 (b): Mass spectra analysis of in vitro oxidation of p-tolyl acetate by CYP101B1. 
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Dihydroactinidiolide oxidation by CYP101B1 occurred with a NADH oxidation rate of ~700 min-1 (Figure 
B.2). In the GCMS analysis of in vitro turnover, the substrate peak is seen at tR = 9.41 min (m/z = 180.05 
AMU) (Figure B.11). Three oxidation products were observed at tR = 12.04 min, 12.21 min and 12.28 
min (Figure 4.12). All the three products correspond to a mass of m/z = 196 AMU (Δm/z = +16 AMU) 
suggesting they arise from monooxygenation (Figure B.11).  






























Figure 4.12: GCMS analysis of the in vitro turnover (zoomed in) of dihydroactinidiolide by CYP101B1 
(black) with substrate control (red). Products are observed at tR = 12.04, 12.21 and 12.28 min. Further 
data given in Figure B.11. 
Other substrates did not display a significant slope to suggest, rapid NADH consumption and therefore 
turnover of the catalytic cycle. However, GCMS analysis was performed on all the in vitro turnovers 
regardless of their ability to display a good NADH consumption. Little or no product was observed for 
all these substrates. For example, the 4-(trans-4-propylcyclohexyl) cyclohexanone, which on addition 
to the in vitro turnover by CYP101B1 induced a poor NADH decay similar to the leak rate (Figure B.2). 
The GCMS analysis of this turnover did not show any signs of product formation (Figure 4.13 (a)). The 
undecanoic--lactone turnover by CYP101B1 was run on GCMS shows that product is generated 
(Figure 4.13 (b)). However, the product could not be rationalised as simple oxy-functionalised 
metabolite based on its mass spectrum. This analysis was complicated by the fragmentation of the 
molecule. 










































































































Figure 4.13: GCMS analysis of the in vitro turnover of (a) 4-(trans-4-propylcyclohexyl) cyclohexanone 
and (b) Undecanoic--lactone by CYP101B1 (black) with substrate control (red). The impurities are 
marked as (*) and the internal standard is denoted by (I.S.). 
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CYP101C1 was less selective than CYP101B1 for in vitro turnovers with decalones. For example, the in 
vitro turnover of trans-1-decalone by CYP101C1 (Figure 4.14) generated seven metabolites, which 
were different from the three metabolites generated by the in vitro turnover of trans-1-decalone by 
CYP101B1 (Figure 4.14 (a)). The GCMS analysis of the peaks at tR = 7.15, 7.48, 7.75, 8.34, 10.04 min 
suggests that they are monooxygenase product (Δm/z = +16 AMU) (Figure 4.14). The peaks at tR = 7.86 
min had a mass of m/z = 150 AMU (Δm/z = -2 AMU) and could arise from a desaturation metabolite 
(Appendix, Figure B.15).   











































Figure 4.14 (a): GCMS analysis of in vitro turnover (zoomed in) of trans-1-decalone with CYP101C1 
(blue) in comparison to CYP101B1 (black) and substrate control (red). The impurities are marked as 
(*) and the internal standard is denoted as (I.S.). Further data given in Figure B.6, B.12. 
MS analysis of major product of in vitro oxidation of trans-1-decalone by CYP101C1 at tR = 8.34 min 
(m/z = 168.100 AMU, Δm/z = + 16 AMU)  
 
MS analysis of major product of in vitro oxidation of trans-1-decalone by CYP101B1 at tR = 9.06 min 
(m/z = 168.050 AMU, Δm/z = + 16 AMU)  
 
Figure 4.14 (b): Mass spectra comparison of the major product of trans-1-decalone on in vitro 
oxidation by CYP101C1 (top) and CYP101B1 (bottom). Further information is provided in Appendix-B, 
Figure B.12.  
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Similarly, the GCMS analysis of the in vitro turnover of 2-decalone by CYP101C1 shows that it 
generated five metabolites (Figure 4.15). The metabolite at tR = 8.40 min has a mass suggesting it to 
be a monooxygenase metabolite (m/z = 168.05 AMU, Δm/z = +16 AMU), it also co-eluted with the 
metabolite generated from the in vitro turnover of 2-decalone by CYP101B1. All the other metabolites 
were different from those generated using CYP101B1 (Figure 4.15). These metabolites exhibited a 
mass suggesting they were all monooxygenase products (Δm/z = + 16 AMU, Figure B.13). 






































Figure 4.15: GCMS analysis of the in vitro turnover (zoomed in) of 2-decalone by CYP101C1 (blue) in 
comparison with CYP101B1 (black) and substrate control (red). The impurities are marked as (*). 
Further data given in Figure B.7, B.13. 
In the case of dihydroactinidiolide, CYP101C1 was more selective, the in vitro oxidation generated a 
single product at tR = 10.03 min (Figure 4.16). This peak was not observed in the in vitro oxidation by 
CYP101B1 (Figure 4.16). The MS analysis for this peak suggests that it is a monooxygenase product 
with a mass corresponding to m/z = 196.2 AMU (Δm/z = +16 AMU) (Figure B.14).  
































Figure 4.16: GCMS analysis of in vitro turnover (zoomed in) of dihydroactinidiolide with CYP101C1 
(blue) in comparison to CYP101B1 (black) and substrate control (red). The impurities are marked as 
(*). Further data given in Figure B.11, B.14. 
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An additional metabolite was observed at tR = 11.06 min upon GCMS analysis of the in vitro oxidation 
of oxacyclotridecan-2-one by CYP101C1 which was absent in its oxidation by CYP101B1. The other 
metabolites generated by the oxidation of oxacyclotridecan-2-one by CYP101B1 at tR = 12.12 min and 
13.17 min, were also generated by CYP101C1 (Figure 4.17). The mass spectra for all three of these 
metabolites suggests that they are monooxygenase products (Δm/z = +16 AMU; Figure B. 15). 






























Figure 4.17: GCMS analysis of in vitro turnover (zoomed in) of oxacyclotridecan-2-one with CYP101C1 
(blue) in comparison to CYP101B1 (black) and substrate control (red). The impurities are marked as 
(*). Further data given in Figure B.10, B.15. 
The CYP101C1 enzyme was unable to oxidise any other of the selected substrates. For example, 
muscone was observed as one of the tightest binding substrate with CYP101B1 with a dissociation 
constant of kd = 0.27 ± 0.05 μM (Figure 4.18 (a)), generating a single major product but its in vitro 
oxidation by CYP101C1 did not generate any significant oxidation metabolite (Figure 4.18 (b)). 
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Figure 4.18: (a) Dissociation constant analysis of muscone with CYP101B1.  (b)GCMS analysis of in vitro 
turnover (zoomed in) of muscone with CYP101C1 (blue) in comparison to CYP101B1 (black) and 
substrate control (red). The impurities are marked as (*). Further data given in Figure B.9.  
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After analysing the spin-state studies and the in vitro studies, for the selected substrates (Figure 4.5) 
with both CYP101B1 and CYP101C1, five substrates (Figure 4.19) were chosen for scale up with the 
whole-cell turnover system. The CYP101B1 enzyme is observed to oxidise the substrates more 
efficiently generating larger quantities of metabolite compared to the CYP101C1 enzyme. Hence, this 
enzyme was used for the whole-cell turnovers. The products were then extracted and separated by 
flash chromatography using a hexane-ethyl acetate system ranging from 5% to 60% ethyl acetate. Due 
to absence of a chromophore group in most of the substrates, the separation could not be performed 
on HPLC.  
 
Figure 4.19: Structure of substrates chosen for whole-cell oxidation. 
The oxidation of dihydroactinidiolide by CYP101B1, induced a NADH oxidation rate of 564 ± 45 min-1. 
However, the product formation rate (33 ± 4 min-1) and the coupling efficiency (6%) were low. The 
whole-cell oxidation system generated a major product (tR = 12.21 min, Figure 4.20) which was 
separated by flash chromatography and characterised as the 6-hydroxy-dihydroactinidiolide by NMR 
analysis (Figure 4.21). The other two metabolites (tR = 12.04 min and 12.28 min) were not generated 
in sufficient quantity to be characterised. 


































Figure 4.20: GCMS analysis of the in vitro turnover (zoomed in) of dihydroactinidiolide by CYP101B1 
(black) in comparison with in vivo (blue) and substrate control (red).  





Figure 4.21 (a): 1H NMR of 6-hydroxy-dihydroactinidiolide in CDCl3. The signal for H5’ is partly visible 
in the range 1.80-1.76 ppm and partly hidden behind the signal for H12 at 1.78 ppm (b): 13C NMR of 
6-hydroxy-dihydroactinidiolide in CDCl3. Impurity is marked as (*) Further data provided in Appendix-
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Oxacyclotridecan-2-one binds to CYP101B1 with a high dissociation constant (Kd = 3.5 ± 0.2 μM) (Figure 
4.22 (a), Table 4.3). It was oxidised with a NADH oxidation rate of 423 ± 5 min-1. The product formation 
rate and the coupling efficiency were observed as 307 ± 81 min-1 and 72% (Table 4.3). The whole-cell 
oxidation system, generated a single product at tR = 12.10 min (Figure 4.22). It was separated from the 
substrate using flash chromatography. The products were present as a mixture along with impurities 
that could not be separated. However, the products were distinguished via 13C NMR carbon signals 
(Figure 4.23 (a)) based on their relative intensities (Table 4.4). The two products could not be 
completely characterised. However, the 13C NMR depicts a total of 24 signals (12 for each compound), 
the signals for the carbonyl group (C=O) around 176 ppm region, the carbon next to ester (CH2O) 
around 72 ppm region and the hydroxylated carbon (CHOH) around 66-67 ppm region (Table 4.4). 
Later these signals were matched to the 1H NMR using HSQC NMR (Figure 4.23 (b)) and the carbon 
next to them could be identified by HMBC NMR. In HMBC NMR we can see that the signal for C1 at 
176 ppm correlates with three CH2 signals, which do not correlate to the signal for hydroxylated 
carbon (CHOH). Also, the signal at 72 ppm (CHOH) is next to three CH2 signals and the signal for C12 
(CH2O) is next to three different CH2 signals which do not relate to the CHOH signal. This suggests that 
the oxacyclotrideca-2-one could be hydroxylated opposite to the ester group at C6, C7 or C8. The 
remaining carbon signals could not be assigned due to their close vicinity with other signals and the 
specific site of hydroxylation could not be determined. This data agrees to the reported data that in 
case of cyclic ketones and cyclic esters, CYP101B1 preferred to hydroxylate the substrate at the carbon 
opposite to the respective ketone and ester functional group [105]. 
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Figure 4.22: (a) Dissociation constant analysis of oxacyclotridecan-2-one with CYP101B1. (b) GCMS 
analysis of the in vitro turnover (zoomed in) of oxacyclotridecan-2-one by CYP101B1 (black) in 
comparison with in vivo (blue) and substrate control (red). The impurities are marked as (*) and the 
internal standard is denoted as (I.S.). Further data given in Figure B.10. 
Table 4.3: Substrate binding and in vitro turnover data for CYP101B1 with selected substrate.  





Oxacyclotridecan-2-one 70 3.5 ± 0.2 423 ± 5 307 ± 81 72 
Dihydroactinidiolide 20 * 564 ± 45 33 ± 4 6 
trans 1-Decalone 60 180 ± 8 224 ± 2 37 ± 3 16  
Cyclopentadecanone 75 0.2 ± 0.09 126 ± 4 47 ± 3 38 
Muscone 60 0.27 ± 0.05  61 ± 3  10 ± 2 17 
*Kd not calculated due to the low spin state shift. NADH is the NADH oxidation rate, PFR is the product 
formation rate, C % is the coupling efficiency, HS% is the spin state shift, Kd is the dissociation constant. 
Rates are reported as mean ± S.D. (n ≥ 3) and given in nmol per nmol CYP per min. 






Figure 4.23: (a) 13C NMR of oxacyclotridecan-2-one oxidation products and impurity. The details of 
assignment of the carbon peak are mentioned in Table 4.4. (b)HSQC NMR of a mixture of 
oxacyclotridecan-2-one products and impurity and impurity. Further data is given in Appendix-B 
(Figure B.22). 
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Table 4.4: Assignment of oxacyxlotridecan-2-one metabolites using 13C NMR. The figures depict the 
possible site of hydroxylation (C6/C7/C8). The chiral centre is marked as (*) in the figure. The peak at 
72.95 ppm is taken as reference to calculate the integral for other peaks. 
 
ppm Integral Intensity Compound-1 Compound-2 
176.59 0.37 59.7  C1 
176.54 0.45 62.2 C1  
72.95 1 (ref) 144.2 COH  
72.65 0.94 132.3  COH 
67.32 1.17 172.2 C12  
66.68 1.13 159.4  C12 
37.62 1.0 224.2  CH2 
37.61 1.50 228.6 CH2  
37.22 1.18 176.5 C2  
37.13 1.11 182.9  C2 
36.18 1.16 172.5  CH2 
36.09 1.16 182.6 CH2  
30.22 1.13 173.1  C11 
29.85 1.15 192.4 C11  
29.32 1.26 197.8 CH2  
29.02 1.05 178.0  CH2 
28.93 1.07 182.3  CH2 
27.33 1.29 189.7 CH2  
26.95 1.28 185.2  CH2 
26.79 1.21 196.8 CH2  
26.00 1.20 190.3 CH2  
24.33 1.29 173.5  CH2 
24.25 1.18 180.9 CH2  
23.45 1.14 176.3  CH2 
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p-Tolyl acetate binds to CYP101B1 with a dissociation constant of Kd = 154 ± 4 μM. Its whole-cell 
oxidation by CYP101B1, generated two metabolites at tR = 8.0, 14.01 min (Figure 4.24), both 
monohydroxy metabolites. The peak at tR = 3.01 coeluted with the internal standard (p-cresol) which 
was also generated in the whole-cell oxidation from ester hydrolysis. The metabolite at tR = 6.58 min 
was not generated in sufficient quantity to be characterised by NMR analysis but has been identified 
as 4-hydroxybenzyl alcohol by GCMS analysis. The metabolite at tR = 8.0 min was separated 
successfully and characterised as 7-hydroxy-p-tolyl acetate by NMR analysis (Figure 4.25). 
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Figure 4.24: (a) GCMS analysis of the in vitro turnover of p-tolyl acetate by CYP101B1 (black) in 
comparison with in vivo (blue) and substrate control (red). The impurities are marked as (*) and the 
internal standard is denoted as (I.S.). (b) Dissociation constant analysis of p-tolyl acetate with 
CYP101B1.  
 





Figure 4.25 (a): 1H NMR for 7-hydroxy-p-tolyl acetate. (b): 13C NMR for 7-hydroxy-p-tolyl acetate. 
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trans-1-Decalone binds to CYP101B1, with lower affinity than the other substrate with Kd = 180 ± 8 
μM (Table 4.3). The substrate was oxidised with NADH oxidation rate of 224 ± 2 min-1 and product 
formation rate of 36.8 ± 3 min-1 (Table 4.3), the coupling efficiency was 16%. trans-1-Decalone was 
oxidised by CYP101B1 in a whole-cell oxidation system to generate three metabolites which were also 
generated during the in vitro oxidation (Figure 4.26). The peak at tR = 9.46 min (Figure 4.26 (b)) was 
observed as split peak of two different metabolites in the whole-cell turnover whereas it was observed 
as a single peak in the in vitro turnover (Figure 4.26 (b)). Both of these metabolites had a mass of (m/z 
= 168 AMU, Δm/z = +16 AMU), which suggests that they are monohydroxylated products. The 
products were extracted with ethyl acetate from the whole-cell turnover system and separated using 
flash chromatography. The metabolites were separated in two different fractions (Figure 4.26 (c)). The 
first fraction consisted of the metabolite at tR = 9.06 min as the major component whereas, the second 
fraction consisted of the metabolite at tR = 9.46 min as the major component. The major product of 
the first fraction was identified as 6-hydroxy-trans-1-decalone by comparing its 13C NMR spectrum 
(Figure 4.27) and mass spectral data to the literature (Table 4.5) [107]. Whereas, the minor product at 
tR = 9.46 min was characterised as 7-hydroxy-trans-1-decalone using NMR analysis (Table 4.5). The 1H 
signal for H6 was assigned by observing its coupling to H5 in gCOSY NMR. The signal for H7 is observed 
to couple to H6 and H8 by gCOSY NMR. By analysing HMBC NMR, a clear correlation between C7 and 
H8, H9 is seen. This confirms the generated product as 7-hydroxy-trans-1-decalone. 
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Figure 4.26 (a): Dissociation constant analyses of trans-1-decalone with CYP101B1. (b) GCMS analysis 
of the in vitro turnover (zoomed in) of trans-1-decalone by CYP101B1 (black) in comparison with 
whole-cell turnover (blue) and substrate control (red). (c) GCMS analysis of fraction 1 (black) and 
fraction 2 (blue) along with substrate control (red). The impurities are marked as (*). Further data 
given in Appendix-B, Figure B.6. 
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Table 4.5: 13C NMR data of 6-hydroxy-trans-1-decalone by comparison to the literature data and 
experimental data for 7-hydroxy-trans-1-decalone metabolite [107]. The assignment of both the 
metabolites has been further confirmed by a DEPT NMR analysis (Figure B.25 (f), Figure B.26 (g)). 
Major product fraction-1  
6-hydroxy-trans-1-decalone (tR = 9.06 min) 
Major product fraction -2  
7-hydroxy-trans-1-decalone (tR = 9.46 min) 
assignment experimental 
data (in ppm) 
literature 
data (in ppm) 
assignment experimental data (in ppm) 
C1 211.80 211.61 C1 211.06 
C6 75.06 74.91 C7 70.49 
C10 53.25 53.11 C10 52.87 
C5 51.61 51.49 C5 43.81 
C2 41.54 41.39 C2 41.35 
C7 35.16 35.03 C4 34.86 
C9 28.21 28.07 C6 34.58 
C4 26.02 25.88 C9/C8a 32.26 
C8 24.58 24.43 C9/C8a 32.17 
C3 22.70 22.56 C3 26.31 
a Due to the presence of both the C8 and C9 signal in a very close vicinity, they could not be identified 
individually. 
 
Figure 4.27 (a): 13C NMR for 6-hydroxy-trans-1-decalone in CDCl3 along with impurities. Further data 
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Figure 4.27 (b): 13C NMR for 7-hydroxy-trans-1-decalone in CDCl3 along with impurities. Further data 
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Cyclopentadecanone binds tightly to CYP101B1 with kd = 0.27 ± 0.05 μM (Figure 4.28 (a)) compared 
to oxacyclotridecan-2-one and trans-1-Decalone (Table 4.3). It exhibits a NADH oxidation rate of 126 
± 4 min-1 and product formation rate of 47 ± 3 min-1 (Table 4.3). The coupling efficiency was 38%, which 
was lower than oxacyclotridecan-2-one but higher compared to trans-1-decalone, muscone and 
dihydroactinidiolide (Table 4.3). The whole-cell oxidation of cyclopentadecanone with CYP101B1 
generated a single major product as observed at tR = 15.08 min (m/z = 240 AMU, Δm/z = +16 AMU) 
(Figure 4.28 (b)), which was separated using flash chromatography and identified as 8-hydroxy-
cyclopentadecanone by comparing the NMR data and mass spectra data to literature [106, 108]. A 
second metabolite was observed only in 13C NMR (Table 4.6, Figure 4.29). This metabolite has similar 
signals as 8-hydroxy metabolite in HSQC and HMBC NMRs [106, 108]. This impurity could be the reason 
for the broad signal of the product in GCMS.  
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Figure 4.28: (a) Dissociation constant analysis of cyclopentadecanone with CYP101B1. (b) (b) GCMS 
analysis of the in vitro turnover (zoomed in) of cyclopentadecanone by CYP101B1 (black) in 
comparison with whole-cell turnover (blue) and substrate control (red). 
 
Figure 4.29: 13C NMR of a mixture of 8-hydroxy-cyclopentadecanone diastereomers and impurity. 
The details of assignment of the carbon peak are mentioned in Table 4.6.   
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Table 4.6: Comparison of cyclopentadecanone metabolite using 13C NMR signals with reference data 
[106, 108]. NMR given in Figure B.21. Intensity is mentioned to approximate the relative amount of 
the compounds present. 
Experimental 
data (in ppm) 
Intensity Reference 
data (in ppm) 
Conformational 
isomer 
214.99 53.6  C1 
215.20 22.6 215.30 (C1)  
72.98 129.1  C8 
72.71 56.8 72.70 (C8)  
44.86 67.8 44.86 (C2)  
44.74 154.7  C2 
44.57 172.4 44.56 (C15) C15 
37.85 150.0  C7 
37.39 67.9 37.35 (C7)  
37.33 166.4 37.30 (C9) C9 
30.70 163.2  C5 
30.24 152.0  C13 
30.21 72.2 30.18 (C5)  
30.18 66.0 30.16 (C13)  
29.66* 85.5 29.64 (C4), 
29.63(C11) 
 
29.53 69.2 29.51 (C12)  
29.38 163.2  C11 
29.36 159.9  C4 
29.31 165.7  C12 
26.26 71.6 26.26 (C3)  
26.11 157.3  C3 
25.97 147.0  C6 
25.93 69.7 25.90 (C6)  
25.80 157.3  C14 
25.71 69.2 25.70 (C14)  
25.49 66.9 25.45 (C10)  
25.22 145.9  C10 
* Signal present as a doublet. 
 
  




CYP101B1 and CYP101C1 can oxidise a variety of substrates, though optimal catalytic activity seems 
to be achieved for norisoprenoids [14, 76]. CYP101B1 has also been reported to efficiently oxidise 
certain monoterpenoid acetates. Many of these share common characteristics with norisoprenoids, 
having a carbonyl group on a side chain attached to a cyclohexyl or bicyclic ring system [91]. Along 
with this, substrates like cyclic ketones and substrates with an ester directing group have been shown 
previously to enhance the oxidation activity of CYP101B1 [91]. 
Amongst the tested substrates, CYP101B1 showed a significant type-I spin-shift with five substrates. 
CYP101B1 also generated significant amount of oxidation metabolites for these substrates. Whereas, 
in case of CYP101C1, none of the substrates showed a spin state shift higher than 10% HS. This 
indicates that the substrates were better suited to fit in the active site pocket of the CYP101B1 but 
not CYP101C1. The GCMS analysis of the oxidation metabolites from CYP101C1 turnover suggests that 
in some cases even with a low spin state shift, the substrate was oxidised. The CYP101C1 enzyme was 
more selective than CYP101B1, in case of dihydroactinidiolide, whereas less selective for trans-1-
decalone and 2-decalone and oxacyclotridecan-2-one.  
The whole-cell oxidation of dihydroactinidiolide generated a single major product with CYP101B1 (> 
90%, tR = 12.21 min) alongside two other metabolites, which was confirmed as the 6-hydroxy-
dihydroactinidiolide. This suggests that the active site of CYP101B1 interacts with the keto group of 
the substrate, orienting the C6 closest to the heme centre. This aligns with the previously reported 
data that CYP101B1 oxidises the substrate at the position opposite to the keto group.  
The GC analysis of oxacyclotridecan-2-one with CYP101B1 seemingly only generated a single major 
product at tR = 12.10 min in the whole-cell turnover. However, the NMR analysis shows the presence 
of two different species.  This was characterised to be hydroxylated opposite to the keto group, but 
the exact location of the hydroxylated position could not be determined from the NMR analysis. 
Whereas, in the in vitro turnover two metabolites were generated in majority. This suggests that the 
metabolite at tR = 13.1 min might be hydrolysed to generate the 6-hydroxy metabolite over time. 
p-Tolyl acetate was oxidised by CYP101B1 in whole-cell turnover to generate the same products as in 
the in vitro turnover. Interestingly the substrate was also degraded during the whole-cell turnover to 
generate p-cresol, which was confirmed by coelution experiment. This could arise from the hydrolysis 




Figure 4.29: Hydrolysis of p-tolyl acetate and 7-hydroxy-p-tolyl acetate.  
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The whole-cell oxidation of trans-1-decalone generated three oxidation metabolites which could not 
be separated from each other using silica chromatography. The absence of a chromophore made 
separation by HPLC difficult. The metabolite at tR = 9.06 min was assigned as 6-hydroxy-trans-1-
decalone by comparing the higher intensity peaks of 13C NMR signals to the literature data [107]. The 
other oxidation product at tR = 9.46 min was characterised as 7-hydroxy-trans-1-decalone by NMR 
analysis. We have reported previously (Chapter 3) that in case of damascones, the carbonyl group 
interacts with the active site orienting the C3 and C4 position closest to the heme for oxidation. Hence, 
the 6-hydroxy metabolite can be compared to the 4-hydroxy oxidation metabolites of damascones 
and the 7-hydroxy metabolite by trans-1-decalone oxidation resembles the 3-hydroxy metabolite of 
damascones.  
 Cyclopentadecanone has been reported previously to generate the 8-hydroxy metabolite as the single 
major product in whole-cell oxidation by CYP101B1 [106, 108]. This was confirmed by comparing the 
13C NMR signal to the literature data [108]. However, this 8-hydroxy metabolite was present as a 
mixture of conformational isomers along with a small amount of cyclopentadecane-1,8-dione. The 
carbon signal of the two conformers were separated from each other by their relative intensities. The 
tight binding observed with this substrate suggests that the active site pocket of CYP101B1 is a good 
fit for large cyclic ketones.  
 In summary, the screening of various different substrates (Figure 4.5) with CYP101B1 and CYP101C1, 
demonstrated that, in most instances the CYP101B1 enzyme is better suited for their selective 
oxidation and capable of generating metabolites in a good yield and often with high selectivity. None 
of the substrates tested closely resemble the physiological substrate of CYP101C1. However, the tight 
binding and a high spin state shift in case of cyclopentadecanone and muscone suggest that these 
substrates might resemble or are closely related to the physiological substrate of CYP101B1.  
 




Conclusions and Future directions 
 
CYP101B1 and CYP101C1 are valuable additions to the field of monooxygenase biocatalysis. These 
enzymes are stable, produced in good yield and their electron transfer partners are known. They have 
been shown to efficiently oxidise norisoprenoids. This work was started to analyse the oxidation of 
norisoprenoid substrates and to study the role played by the functional group (ketone versus alcohol) 
on the butenyl side chain and the role of alkene moiety inside the cyclohexyl ring. We have also 
analysed, whether the M82L mutation in the active site of CYP101C1 enzyme alters the activity and 
selectivity for norisoprenoid substrates.  
In chapter-3, we observed that the spin-state shift induced by norisoprenoids is always higher for 
CYP101B1 in comparison to CYP101C1 but the activity (NADH oxidation rate and product formation 
rate) of damascone substrates (− − −) were higher with WT-CYP101C1 but that of ionones were 
higher with CYP101B1. This suggests that altering the ketone group on the butenyl side chain increases 
the activity for CYP101C1. In terms of selectivity for hydroxylation, the M82L-CYP101C1 mutant was 
similar to the WT-CYP101C1 enzyme and did not cause any significant alteration to the expected site 
of hydroxylation. In agreement to the crystallographic data, this work shows that the C3 and C4 
carbons are held closest to the heme centre and hence they are the preferred site of hydroxylation 
for norisoprenoid substrates. Observing the oxidation of -ionol we found that both all three enzymes 
prefer the C3 position instead of C4 for hydroxylation. This shows that changing the keto group of the 
substrate can alter the selectivity of the enzyme. We also observed that the alkene moiety present 
inside the cyclohexyl ring plays a crucial role in deciding the site for hydroxylation. With −substituted 
ionone and damascone we observed that the position of the keto group on the butenone side chain 
affects the hydroxylation. The hydroxylation of -damascone shows that a 2-hydroxy metabolite can 
be generated from allylic hydroxylation.  
The spin-state shifts used to access the substrate binding with the M82L-CYP101C1 mutant were 
consistently lower than 20% HS (except for -ionone). The total turnover number was also lower 
compared to the WT-CYP101C1 and WT-CYP101B1 enzymes. This shows that simply changing the 
methionine residue does not significantly increase the affinity of CYP101C1 towards norisoprenoid 
substrates. Mutagenesis experiments could be undertaken with CYP101C1 by altering other active site 
residues or by changing the methionine to an amino acid other than leucine, such as histidine to 
increase its activity towards norisoprenoid substrates. Further optimisation of the whole-cell oxidation 
system to generate the minor metabolites in a higher yield could provide more insight into the regio 
and stereo selectivity of the enzymes. The NMR characterisation of the -ionol products could give a 
better insight of the selectivity by CYP101B1 and CYP101C1. 
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In Chapter-4, a range of diverse substrates containing a carbonyl or an ester or amide directing group 
were tested with CYP101B1 and CYP101C1 to explore their substrate range. However, most of the 
substrates induced a spin-state shift lower than 40% HS with CYP101B1 and none of the substrate 
showed a spin-state of more than 10% HS with CYP101C1. Analysing this data along with the in vitro 
turnover data, the best enzyme / substrate combinations were chosen for whole-cell turnover system 
to generate their oxidation metabolites in a higher quantity for characterisation. Substrates such as 
oxacyclotridecan-2-one, p-tolyl acetate, decalones, dihydroactinidiolide and the cyclic ketones, 
muscone and cyclopentadecanone, induce a better spin state-shift and have a higher product 
formation activity than the others. The high spin state shift and tight binding of muscone and 
cyclopentadecanone with CYP101B1 suggest that they could be a good fit to the active site pocket of 
CYP101B1 enzyme. The substrates used with the whole-cell oxidation system aligns with those 
previously reported for CYP101B1 enzyme. This enzyme preferred to hydroxylate these substrates at 
the carbon opposite to the keto or ester functional group. In future works, these substrates should be 
used for whole-cell or in vitro oxidation by CYP101C1 to provide an insight on the difference in 
selectivity.  
Absence of a chromophore in substrates like oxacyclotridecan-2-one, cyclopentadecanone and 
muscone, makes the separation of oxidation metabolites by HPLC for these substrates more 
challenging. In future, these substrates can be functionalized with a chromophore for a more reliable 
separation of the metabolites to help in their characterisation. 
In case of trans-1-decalone and 2-decalone, desaturation and hydroxylated metabolites (Figure 5.1) 
standards could be bought for use as standards for coelution experiments and to compare their mass 
spectra. This could give a better insight in the catalytic activity of CYP101B1 and CYP101C1 towards 
the decalone substrates. 
 
Figure 5.1: Structure of trans-1-decalone and 2-decalone metabolites available for purchase online. 
With p-tolyl acetate, the oxidation metabolites were unstable with ester hydrolysis being observed. 
However, the major product was identified as 7-hydroxy-p-tolyl acetate by NMR analysis.  4-
Hydroxybenzyl alcohol was also detected by comparing the mass spectra to the available NIST data 
(MS number: 231451). This product was presumably generated from the hydrolysis of the major 
product. p-Cresol was also generated during the whole-cell oxidation, which was confirmed by 
coelution experiment. This could be generated from hydrolysis of the p-tolyl acetate substrate. 
Overall, the substrates with a keto group or an ester group are well suited for oxidation by CYP101B1 
but the substrate range for CYP101C1 is less clear. In future, keeping in mind the substrates which are 
good fit with CYP101C1, a different range of molecules which mimic norisoprenoids should be 
screened with both CYP101B1 and CYP101C1. Also, in case of Undecanoic-d-lactone, further 
investigation is required to analyse, if other changes in the molecules have occurred during the 
turnover. For example, hydrolysis of the ester group. Further work is also required to understand the 
conformation of these large ring substrates in the active site of these P450 enzymes. 
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Appendix-A (Data for Chapter-3) 
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Figure A.1:  Spin state shifts and dissociation constant for a) -damascone and b) δ-damascone with 
WT-CYP101B1. 
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Figure A.2: Spin state shifts of aforementioned substrates with WT-CYP101C1. 
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Figure A.3: Dissociation constant of aforementioned substrates with WT-CYP101C1. 
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Figure A.4: Spin state shifts of aforementioned substrates with M82L-CYP101C1. 
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Figure A.5: Dissociation constant of aforementioned substrates with M82L-CYP101C1. 
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Figure A.6: Calibration data of aforementioned substrates. The slope (m) of the calibration curve is 
used to determine the amount of metabolites generated in turnovers. 
 
Table 3.2: Slopes of calibration curves for norisoprenoid substrates 
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NMR Analysis 
Data for cis-3-hydroxy-α-ionone [76]: 
1H NMR (500 MHz, CDCl3) δ 6.54 (dd, J = 15.8, 10.1 Hz, 1H’; H7), 6.11 (d, J = 15.8 Hz, 1H’; H8), 5.64 (s, 
1H’; H4), 4.28 (s, 1H’; H3), 2.51 (d, J = 10.1 Hz, 1H’; H6), 2.27 (s, 3H’; H10), 1.85 (dd, J = 13.5, 5.9 Hz, 
1H’; H2a), 1.63 (s, 3H’; H13), 1.42 (dd, J = 13.5, 5.9 Hz, 1H’; H2b), 1.04 (s, 3H’; H11), 0.90 (s, 3H’; H12); 
Carbon NMR: 13C NMR (126 MHz, CDCl3) δ 200.67 (C9), 149.75 (C7), 138.08 (C5), 136.26 (C8), 128.48 
(C4), 68.11 (C3), 56.93 (C6), 46.48 (C2), 36.50 (C1), 31.96 (C11), 29.86 (C10), 27.34 (C12), 25.31 (C13). 
 
  
Figure A.7 (a) 1H NMR of cis-3-hydroxy-α-ionone in CDCl3. Impurity / OH (*). 
  
* * 
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Data for trans-3-hydroxy-α-ionone [76]: 
1H NMR: 1H NMR (500 MHz, CDCl3) δ 6.64 (dd, J = 15.8, 9.6 Hz, 1H’; H7), 6.09 (d, J = 15.8, 9.6 Hz, 1H’; 
H8), 5.60 (s, 1H’; H4), 4.21 – 4.31 (m, 1H’; H3), 2.27 (m, 4H’; H6, H10), 1.69 – 1.73 (m, 1H’; H2a), 1.64 
(s, 3H’; H13), 1.38 - 1.44 (m, H’; H2b), 0.99 (s, 3H’; H11), 0.90 (s, 3H’; H12); 13C NMR (126 MHz, CDCl3) 
δ 200.94 (C9), 150.29 (C7), 138.12 (C5), 135.39 (C8), 129.02 (C4), 69.11 (C3), 56.98 (C6), 43.40 (C2), 




Figure A.8 (a): 1H NMR of trans-3-hydroxy-α-ionone in CDCl3. Impurity / OH (*). H2O (#), The proton 
signal for H6 is shown as a multiplet, which is partly seen at 2.29 ppm and partly hidden behind the 
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Figure A.8 (b): 13C NMR of trans-3-hydroxy-α-ionone in CDCl3. 
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Data for 4-hydroxy-β-ionone [109]: 
1H NMR (500 MHz, CDCl3) δ 7.20 (d, J = 16.4 Hz, 1H’; H8), 6.13 (d, J = 16.4 Hz, 1H’; H7), 4.02 (s, 1H’; 
H4), 2.32 (s, 3H’; H10), 1.96 – 1.90 (m, 1H’; H3a), 1.86 (s, 3H’; H13), 1.78 – 1.71 (m, 1H’; H3b), 1.70 – 
1.64 (m, 1H’; H2a), 1.45 – 1.49 (m, 1H’; H2b), 1.09 (s, 3H’; H11), 1.06 (s, 3H’; H12); 13C NMR (126 MHz, 
CDCl3) δ 200.96 (C9), 145.23 (C8), 142.08 (C6), 136.53 (C5), 135.75 (C7), 72.58 (C4), 37.31 (C2), 31.49 
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Figure A.9 (b): 13C NMR of 4-hydroxy-β-ionone in CDCl3. 
  
95 | P a g e  
 
Data for 3-hydroxy-β-ionone [76]: 
1H NMR (500 MHz, CDCl3) δ 7.22 (d, J = 16.4 Hz, 1H’; H8), 6.12 (d, J = 16.4 Hz, 1H’; H7), 4.04 – 3.99 (m, 
1H’; H3), 2.45 (dd, J = 17.5, 1H’; H4a), 2.31 (s, 3H’; H10), 2.10 (dd, J = 17.5 Hz, 1H’; H4b), 1.82 - 1.79 
(m, 4H’; H2a, H13),  1.53 – 1.48 (m, 1H’; H2b), 1.13 (s, 3H’; H11), 1.12 (s, 3H’; H12); 13C NMR (126 MHz, 
CDCl3) δ 201.09 (C9), 144.91 (C8), 138.30 (C6), 135.04 (C5), 134.83 (C7), 67.20 (C3), 51.09 (C2), 45.42 




Figure A.10 (a): 1H NMR of 3-hydroxy-β-ionone in CDCl3. impurity (*), CDCl3 (#). The signal for H2a is 
present as a multiplet, which is partly visible at 1.81 ppm and partly hidden behind the signal for H13 
at 1.79 ppm. 
  
# 
* † * 
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Figure A.10 (b): 13C NMR of 3-hydroxy-β-ionone in CDCl3. 
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Data for anti-3-4-dihydroxy-β-ionone **: 
1H NMR (500 MHz, CDCl3) δ 7.15 (d, J = 16.4 Hz, 1H’; H8), 6.13 (d, J = 16.4 Hz, 1H’; H7), 3.95 (d, J = 7.8 
Hz, 1H’; H4), 3.81 (ddd, J = 12.4 Hz, 7.8 Hz, 3.5 Hz, 1H’; H3), 2.31 (s, 3H’; H10), 1.83 (s, 3H’; H13), 1.78 
(dd, J = 12.4, 3.5 Hz, 1H’; H2a), 1.62 (t, J = 12.4 Hz, 1H’; H2b), 1.14 (s, 3H’; H11), 1.10 (s, 3H’; H12); 13C 
NMR (126 MHz, CDCl3) δ 200.94 (C9), 144.66 (C8), 140.66 (C6), 136.10 (C7), 135.24 (C5), 80.26 (C4), 
73.24 (C3), 47.24 (C2), 39.53 (C1), 32.85 (C12), 30.81 (C11), 30.14 (C10), 19.01 (C13). 
 
 
Figure A.11 (a): 1H NMR of anti-3,4-dihydroxy-β-ionone in CDCl3. Impurity / OH (*).  
** The NMR was compared to the reported NMRs of 3-cyclohexene-1,2-diol, 1,2-dihydroxy-3,5-
dimethyl-3-cyclohexene and 7-oxabicyclo-[4.1.0]hepy-3-ene. The proton and carbon signals for 3-
cyclohexene-1,2-diol were, Ha = 4.14 ppm; Ca = 68.8 ppm, Hb = 3.83 ppm; Cb = 66.5 ppm. For 1,2-
dihydroxy-3,5-dimethyl-3-cyclohexene it was, Hc = 3.79 ppm; Cc = 69.8 ppm, Hd = 3.59 ppm; Cd = 69.7 
ppm. For 7-oxabicyclo-[4.1.0]hepy-3-ene, He = 3.50 ppm; Ce = 55.2 ppm, Hf = 3.23 ppm; Cf = 47.1 ppm. 
This suggests that the metabolite is 3,4-dihydroxy--ionone. 
* 
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Figure A.11 (b): 13C NMR of anti-3,4-dihydroxy-β-ionone in CDCl3. 
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Figure A.11 (c1): g-COSY NMR of anti-3,4-dihydroxy-β-ionone in CDCl3. 
  






100 | P a g e  
 
 
Figure A.11 (d): HSQC NMR of anti-3,4-dihydroxy-β-ionone in CDCl3. 
 
 
Figure A.11 (e1): HMBC NMR of anti-3,4-dihydroxy-β-ionone in CDCl3 (Range (f2): 7.2-3.6 ppm). 
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Figure A.11 (e2): HMBC NMR of anti-3,4-dihydroxy-β-ionone in CDCl3 (Range (f2): 1-2.6 ppm). 
 
Figure A.11 (f1): ROSEY NMR of anti-3,4-dihydroxy-β-ionone in CDCl3 (Range (f2): 4.6-3.3 ppm). 
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Figure A.11 (f2): ROSEY NMR of anti-3,4-dihydroxy-β-ionone in CDCl3 (Range (f2): 4.6-3.3 ppm). 
The coupling constant suggests that the interaction between H2b and H3 is axial/axial (J2b,3 = 12.4 Hz) 
and that the interaction between H3 and H4 is also axial/axial (J3,4 = 7.8 Hz). The coupling constant for 
2J2a,2b = J2b,3 = 12.4 Hz. The COSY NMR shows interaction of H3 with H2a and H2b (Figure A.11 (c2)). The 
unresolved coupling constant (4J) between H4 and Me13 (Figure A.11 (C2)) is the reason for the 
broadening of H4 signal in 1H NMR.  Also, The ROSEY NMR shows the interaction between H4 and H2b, 
H3 and Me11 (Figure A.11 (f2)). Both these NMRs confirm the structure shown in Figure A.11 (g). 
 
Figure A.11 (g): Half chair structure for anti-3,4-dihydroxy--ionone. R here is the side chain of -
ionone. The blue arrows represent the COSY interactions and the red arrows indicates the ROSEY 
interactions.  
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Data for cis-3-hydroxy--damascone [92]: 
1H NMR (500 MHz, CDCl3) δ 6.92 (dq, J = 13.8, 6.9 Hz, 1H’; H9), 6.33 (dd, J = 13.8, 1.6 Hz, 1H’; H8), 5.70 
(s, 1H’; H4), 4.21 (s, 1H’; H3), 2.94 (s, 1H’; H6), 1.93 (dd, J = 6.9, 1.6 Hz, 3H’; H10), 1.66 (d, J = 8.2 Hz, 
2H, H2a, H2b), 1.61 (s, 3H’; H13), 0.99 (s, 3H’; H12), 0.90 (s, 3H’; H11); 13C NMR (126 MHz, CDCl3) δ 
203.89 (C7), 145.90 (C9), 136.15 (C5), 135.08 (C8), 130.28 (C4), 68.84 (C3), 63.45 (C6), 43.61 (C2), 37.63 
(C1), 31.29 (C11), 30.97 (C12), 25.69 (C13), 20.97 (C10). 
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Figure A.12 (b): 13C NMR for cis-3-hydroxy--damascone in CDCl3. 
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Data for trans-3-hydroxy-α-damascone [92]: 
1H NMR (500 MHz, CDCl3) δ 6.91 (td, J = 13.8, 6.8 Hz, 1H’; H9), 6.24 (dd, J = 13.8, 1.4 Hz, 1H’; H8), 5.72 
(s, 1H’; H4), 4.36 (s, 1H’; H3), 3.14 (s, 1H’; H6), 1.94 – 1.98 (m, 1H’; H2a), 1.92 (dd, J = 6.8, 1.4 Hz, 3H’; 
H10), 1.64 (s, 3H’; H13), 1.39 – 1.43 (m, 1H’; H2b), 1.14 (s, 3H’; H11), 0.90 (s, 3H’; H12); 13C NMR (126 
MHz, CDCl3) δ 203.68 (C7), 145.69 (C9), 135.96 (C5), 134.89 (C8), 130.07 (C4), 68.65 (C3), 63.24 (C6), 
43.42 (C2), 37.43 (C1), 31.08 (C11), 30.77 (C12), 25.49 (C13), 20.77 (C10). 
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Figure A.13 (b): 13C NMR for trans-3-hydroxy--damascone in CDCl3. 
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Data for 4-hydroxy-β-damascone [76]:  
1H NMR (500 MHz, CDCl3) δ 6.78 (dq, J = 13.7, 6.9 Hz, 1H’; H9), 6.17 (dd, J = 13.7, 1.4 Hz, 1H’; H8), 4.01 
(s, 1H’; H4), 2.05 – 1.97 (m, 1H’; H3a), 1.94 (dd, J = 6.9, 1.4 Hz, 3H’; H10), 1.78 (m, 1H’; H3b), 1.70 - 
1.64 (m, 4H’; H10 & H2a), 1.49 – 1.44 (m, 1H’; H2b), 1.05 (s, 6H’; H11 & H12); 13C NMR (126 MHz, 
CDCl3) δ=203.49 (C7), 149.06 (C9), 146.25 (C6), 136.57 (C8), 133.60 (C5), 71.68 (C4), 37.29 (C2), 36.64 





Figure A.14 (a): 1H NMR of 4-hydroxy-β-damascone in CDCl3. Impurity (*), H2O (#). (†) The signal for 
H2a is present as a multiplet signal which is partly visible at 1.7 ppm and partly hidden behind the 
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Figure A.14 (b): 13C NMR of 4-hydroxy-β-damascone in CDCl3. 
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Data for 3-hydroxy--damascone [76]: 
1H NMR (500 MHz, CDCl3) δ=6.78 (dq, J = 15.6, 6.9 Hz, 1H; H9), 6.16 (dd, J = 15.7, 1.6 Hz, 1H; H8), 4.01 
(t, J = 4.9 Hz, 1H; H3), 2.16 (dd, J = 8.6, 5.8 Hz, 1H; H4a), 2.04-1.97 (m, 1H; H4b), 1.94 (dd, J = 6.9, 1.6 
Hz, 3H; H10), 1.79 – 1.74 (m, 1H; H2a), 1.65 (s, 3H; H13), 1.48 – 1.44 (m, 1H; H2b), 1.05 (s, 6H; H11 & 
H12). 13C NMR (126 MHz, CDCl3) δ=203.48 (C7), 149.02 (C9), 145.48 (C6), 136.57 (C8), 132.85 (C5), 




Figure A.15 (a) 1H NNMR for 3-hydroxy--damascone in CDCl3. This product was separated with 
impurity of another monohydroxy product, the signal of second product are labelled as (†). The signal 
of H13 at 1.65 ppm covers a signal from impurity as well. The signal of solvent residue / H2O / OH is 
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Figure A.15 (b): 13C NMR of 3-hydroxy--damascone in CDCl3.  
  
111 | P a g e  
 
Data for 3,4-epoxy-δ-damascone [92]: 
1H NMR (500 MHz, CDCl3) δ=6.84 (dq, J = 15.5, 6.9 Hz, 1H, H9), 6.21 (dq, J = 15.5, 1.7 Hz, 1H, H8), 3.20 
– 3.18 (m, 1H, H3), 2.89 (d, J = 4.0 Hz, 1H, H4), 2.49 (dq, J = 11.6, 7.2 Hz, 1H, H5), 2.20 (d, J = 11.6 Hz, 
1H, H6), 1.94 (dd, J = 1.6 Hz, 1H, H2), 1.90 (dd, J = 6.9, 1.7 Hz, 3H, H10), 1.61 (dd, J = 1.6 Hz, 1H, H2’), 
0.99 (s, 3H, H11), 0.97 (d, J = 7.2 Hz, 3H, H13), 0.87 (s, 3H, H12); 13C NMR (126 MHz, CDCl3) δ 205.53 
(C7), 144.63 (C9), 136.61 (C6), 62.91 (C8), 59.25 (C5), 55.86 (C4), 42.52 (C3), 36.03 (C2), 34.70 (C1), 
31.91 (C11), 25.99 (C12), 21.63 (C10), 20.87 (C13). 
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Figure A.16 (b): 13C NMR of 3,4-epoxy--damascone in CDCl3. 
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Data for 2-hydroxy--damascone: 
1H NMR (599 MHz, cdcl3) δ 6.85 (dq, J = 15.5, 6.8 Hz, 1H; H9), 6.23 – 6.19 (m, 1H; H8), 5.59 – 5.55 (m, 
1H; H4), 5.48 – 5.45 (m, 1H, H3), 3.95 (s, 1H, H2), 2.64 – 2.58 (m, 1H, H5), 2.56 (d, J = 10.0 Hz, 1H; H6), 
1.91 – 1.89 (m, 3H; H10), 0.97 (s, 3H; H11), 0.92 (s, J = 1.5 Hz, 3H; H12), 0.86 (d, J = 6.8 Hz, 3H; H13); 
13C NMR (151 MHz, cdcl3) δ 204.58 (C7), 145.09 (C9), 136.99 (C8), 136.79 (C4), 131.14 (C3), 78.53 (C2), 
62.32 (C6), 40.60 (C1), 34.26 (C5), 28.40 (C11), 22.38 (C13), 20.93 (C10), 16.78 (C12). 
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Figure A.17 (b): 13C NMR of 2-hydroxy--damascone in CDCl3. 
 
Figure A.17 (c): HSQC NMR of 2-hydroxy--damascone in CDCl3. 




Figure A.17 (d): HMBC NMR of 2-hydroxy--damascone in CDCl3. 
 
Figure A.17 (e): g-COSY NMR of 2-hydroxy--damascone in CDCl3. 
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Data for cis-3-hydroxy--ionol [109]: 
1H NMR (500 MHz, CDCl3) δ 5.61 – 5.53 (m, 2H, H7, H4), 5.38 (dd, J = 15.3, 9.8 Hz, 1H, H8), 4.37 – 4.29 
(m, 1H, H9), 4.24 (s, 1H, H3), 2.33 (d, J = 9.8 Hz, 1H, H6), 1.83 (dd, J = 13.2, 5.9 Hz, 1H, H2), 1.62 (s, 3H, 
H10), 1.36 (dd, J = 13.3, 6.7 Hz, 1H, H2), 1.29 (d, J = 6.4 Hz, 3H, H13), 1.01 (s, 3H, H11), 0.85 (s, 3H, 
H12). 13C NMR (126 MHz, CDCl3) δ 140.24 (C8), 140.05 (C5), 131.75 (C4), 127.32 (C7), 71.36 (C9), 68.47 
(C3), 56.65 (C6), 47.06 (C2), 36.05 (C1), 32.03 (C13), 26.88 (C12), 26.28 (C11), 25.28 (C10). 
 
 
Figure A.18 (a): 1H NMR of cis-3-hydroxy--ionol in CDCl3. Impurity (*), H2O (#). (†) Signal for H7 is 
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Figure A.18 (b): 13C NMR of cis-3-hydroxy--ionol in CDCl3. 
 
Figure A.18 (c): HSQC NMR of cis-3-hydroxy--ionol in CDCl3. 
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Figure A.18 (d): HMBC NMR of cis-3-hydroxy--ionol in CDCl3. 
 
Figure A.18 (e): g-COSY NMR of cis-3-hydroxy--ionol in CDCl3.  
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trans-3-hydroxy--ionol [109]: 
1H NMR (500 MHz, CDCl3) δ 5.55 (dd, J = 6.1, 2.5 Hz, 1H, H4), 5.50 (d, J = 9.4 Hz, 2H, H8, H7), 4.32 (p, J 
= 6.6 Hz, 1H, H9), 4.25 – 4.19 (m, 1H, H3), 2.08 (d, J = 9.0 Hz, 1H, H6), 1.66 – 1.62 (m, J = 8.9 Hz, 4H, 
H2, H10), 1.36 (dd, J = 12.6, 9.8 Hz, 1H, H2), 1.31 – 1.27 (m, 3H, H13), 0.94 (s, 3H, H12), 0.86 (d, J = 
10.5 Hz, 3H, H11). 13C NMR (126 MHz, CDCl3) δ 137.57 (C5), 136.45 (C8), 130.26 (C4), 124.77 (C7), 




Figure A.19 (a): 1H NMR of trans-3-hydroxy--ionol in CDCl3. Impurity (*), H2O (#). Signal for H7 is 
partially visible at 5.55 ppm and partly hidden behind the signal for H8. Signal for H2 is partly visible 
at 1.63 ppm and partly hidden behind the signal for H10. The signal for H11 is seen as a doublet in the 




120 | P a g e  
 
 
Figure A.19 (b): 13C NMR of trans-3-hydroxy--ionol in CDCl3, along with some impurities. 
 
Figure A.19 (c): HSQC NMR of trans-3-hydroxy--ionol in CDCl3. 
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Figure A.19 (d): HMBC NMR of trans-3-hydroxy--ionol in CDCl3. 
 
Figure A.19 (e): g-COSY NMR of trans-3-hydroxy--ionol in CDCl3.  
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MS analysis of -ionone substrate (m/z = 192.250 AMU) 
 
MS analysis of trans-3-hydroxy--ionone (m/z=208.250; Δm/z = +16 AMU) 
 
 
MS analysis of cis-3-hydroxy--ionone at (m/z=208.250 AMU; Δm/z = +16 AMU) 
 
 
MS analysis of trans-3-oxo--ionone (m/z = 206.250 AMU; Δm/z = +14 AMU) 
 
Figure A.20: MS data for the In vitro turnover of -ionone with M82L-CYP101C1. 
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MS analysis of -ionone substrate (m/z = 192.250 AMU)  
 
 
MS analysis of 4-hydroxy--ionone (m/z=208.250 AMU; Δm/z = +16 AMU) 
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MS analysis of 3,4-dihydroxy--ionone** (m/z=206.000 AMU; Δm/z = +14 AMU) 
 
** The expected mass for this product is 224 AMU. The peak at 206.000 AMU suggests that there is 
a loss of 18 AMU, which signifies the loss of a H2O molecule from the substrate. The retention time 
on GC and chemical shifts of the hydroxylated site in 1H NMR confirms the product as 3,4-dihydroxy-
-ionone. 
Figure A.21: MS data for the In vitro turnover of -ionone with M82L-CYP101C1. 
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125 | P a g e  
 
MS analysis of -damascone substrate (m/z = 192.200 AMU) 
 
 
MS analysis of cis-3-hydroxy--damascone (m/z=208.200 AMU; Δm/z = +16 AMU) 
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193.200175.200165.200 208.200194.350153.750 160.250 179.450 186.500 200.350
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MS analysis of 3-oxo--damascone (m/z = 206.250 AMU; Δm/z = +14 AMU) 
 
 
Figure A.22: GC-MS data for the In vitro turnover of -damascone with M82L-CYP101C1  
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MS analysis of -damascone substrate (m/z = 192.200 AMU) 
 
 
MS analysis of 4-hydroxy--damascone (m/z=208.05; Δm/z = +16 AMU) 
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157.150 194.250165.200 179.150173.200 210.150189.300
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MS analysis of 3,4-dihydroxy--damascone** (m/z = 206.950 AMU; Δm/z = +14 AMU) 
 
** The expected mass for this product is 224 AMU. The peak at 206.950 AMU suggests that there is 
a loss of 18 AMU, which signifies the loss of a H2O molecule from the substrate. The retention time 
on GC confirms the product as 3,4-dihydroxy--damascone. 
Figure A.23: GC-MS data for the In vitro turnover of -damascone with M82L-CYP101C1. 
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MS analysis of -damascone substrate (m/z = 192.250 AMU) 
 
 
MS analysis of 3,4-epoxy--damascone (m/z=208.200 AMU; Δm/z = +16 AMU) 
 
 
MS analysis of 2-hydroxy--damascone (m/z=208.05; Δm/z = +16 AMU) 
 
 
Figure A.24: GC-MS data for the In vitro turnover of -damascone with M82L-CYP101C1. 
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MS analysis of -ionol substrate (m/z = 194.00 AMU) 
 
 
MS analysis of cis-3-hydroxy--ionol (m/z=210.650 AMU; Δm/z = +16 AMU) 
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MS analysis of 3-oxo--ionol (m/z=208.100 AMU; Δm/z = +14 AMU) 
 
Figure A.25: GC-MS data for the In vitro turnover of -ionol with M82L-CYP101C1. 
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MS analysis of -ionol substrate (m/z = 194.100 AMU) 
 
 
MS analysis of 4-hydroxy--ionol (m/z = 210.05AMU; Δm/z = +16 AMU) 
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185.100181.000
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MS analysis of -ionol product (m/z = 208.050 AMU; Δm/z = +14) 
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168.100 180.850 187.650 197.350154.150 209.900204.600 223.350
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GC-FID data for in vivo turnovers  
 
























































Figure A.27: GC-FID analysis of the in vitro turnover (blue) and in vivo turnover (black) of WT-CYP101C1 with -
ionone in comparison to substrate control (red). Internal standard (†), impurity of -ionol (*), impurity of -
ionone (#). 























































Figure A.28: GC-FID data for whole-cell (black) turnover of -ionone with WT-CYP101C1 in comparison 
to substrate control (red) and in vitro turnover (blue) of -ionone with WT-CYP101C1. Impurity from 
substrate or extraction (*), internal standard (I.S.). 
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Figure A.29: GC-FID data for whole-cell (black) turnover of -damascone with WT-CYP101C1 in 
comparison to substrate control (red) and in vitro turnover (blue) of -damascone with WT-CYP101C1. 
Internal standard (I.S.). 
 
 
























































Figure A.30: GC-FID data for whole-cell (black) turnover of -damascone with WT-CYP101C1 in 
comparison to substrate control (red) and in vitro turnover (blue) of -damascone with WT-CYP101C1. 
Oxidation of impurity (#), unidentified product (@), impurity from substrate or extraction (*), Internal 
standard (I.S.). 
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Figure A.31: GC-FID data for whole-cell (black) turnover of -damascone with WT-CYP101C1 in 
comparison to substrate control (red) and in vitro turnover (blue) of -damascone with WT-CYP101C1. 
Impurity from substrate or extraction (*), Internal standard (I.S.). 
 
























































Figure A.32: GC-FID data for whole-cell (black) turnover of -ionol with WT-CYP101C1 in comparison 
to substrate control (red) and in vitro turnover (blue) of -ionol with WT-CYP101C1.  Internal standard 
(I.S.), unidentified impurity (#). 
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Appendix-B (Data for Chapter-4) 
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Figure B.1: Spin state shift of selected substrates with CYP101B1.  
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Figure B.2: In vitro turnover of selected substrate at 340nm with CYP101B1. 
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Figure B.3: In vitro turnover of selected substrate at 340nm with CYP101C1. 
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Figure B.4: Spin state shift of selected substrate with CYP101C1. 
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Concentration of Substrate (M)
Calibration for Dihydroactinidiolide
 
R2 = 0.9915; m = 0.0107 


















Concentration of Substrate (M)
Calibration for trans-1-decalone
 
R2 = 0.996; m= 0.0065 


















Concentration of Substrate (M)
Calibration for Cyclopentadecanone
 
R2 = 0.998; m = 0.0067 


















Concentration of Substrate (M)
Calibration for Oxacyclotridecan-2-one
 
R2 = 0.9991; m = 0.00996 




















Concentration of Substrate (M)
Calibration for Muscone
 
R2 = 0.999; m = 0.0154 
 
Figure B.5: Calibration data for selected substrates. The slope (m) of the calibration curve is used to 
determine the amount of metabolites generated in turnovers. 
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Figure B.6 (a): GCMS analysis of In vitro turnover of trans-1-decalone by CYP101B1 (black) with 
substrate control (red). Internal standard is marked as (I.S.). Impurities are marked as (*). 
 
MS analysis of trans-1-Decalone substrate at tR = 6.13 min (m/z = 152.1 AMU) 
 
 
MS analysis of 6-hydroxy-trans-1-decalone (tR = 9.06 min) (m/z = 168.050 AMU, Δm/z = + 16 AMU)  
Reported m/z = 168.0, 150.0 and 97.1 [107]. 
Experimental m/z = 168.050, 150.050, 135.050, 121.050, 111.050, 97.000, 93.050, 81.000, 68.050, 
67.000 and 54.950 
 









84.000 119.05065.000 138.050 192.850175.100156.000
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MS analysis of peak at tR = 9.27 min of in vitro oxidation of trans-1-decalone by CYP101B1 (m/z = 
168.150 AMU, Δm/z = + 16 AMU)  
 
MS analysis of 7-hydroxy-trans-1-decalone (tR = 9.46 min) (m/z = 168.000 AMU, Δm/z = + 16 AMU)  
 
Figure B.6 (b): MS analysis of the substrate and oxidation metabolites generated in in vitro turnover 
of trans-1-decalone with CYP101B1. 
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Figure B.7 (a): GCMS analysis of In vitro turnover of 2-decalone by CYP101B1 (black) with substrate 
control (red). Internal standard is marked as (I.S.). Impurities are marked as (*). 
 
MS analysis of 2-decalone substrate at tR = 6.25 (m/z = 152.1 AMU) 
 
MS analysis of 2-decalone substrate at tR = 6.85 min (m/z = 152.1 AMU) 
 







68.000 123.05091.000 105.00051.000 193.100179.100







123.050 134.100105.000 154.050115.000 193.100179.100








123.10065.000 105.050 154.100 183.100
197.100







123.100 134.100105.050 115.050 154.100 165.100 183.100
197.100
195.100175.100
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MS analysis of metabolite at tR=8.40 min (m+/z = 168.05 AMU; Δm/z = +16 AMU) 
 
MS analysis of metabolite at tR=9.53 min (m+/z = 168.05 AMU; Δm/z = +16 AMU) 
 
MS analysis of metabolite at tR=9.86 min (m+/z = 168.05 AMU; +16 AMU) 
 
MS analysis of metabolite at tR=10.02 min (m+/z = 168.05 AMU; +16 AMU) 
 
Figure B.7 (b): MS analysis of the substrate and oxidation metabolites generated in in vitro turnover 
of 2-decalone with CYP101B1.  
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Figure B.8 (a): GCMS analysis of In vitro turnover of cyclopentadecanone by CYP101B1 (black) with 
substrate control (red). Internal standard is marked as (I.S.). Impurities are marked as (*). 
MS analysis of cyclopentadecanone substrate at tR = 12.7 min (m/z = 224.200 AMU) 
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MS analysis 8-hydroxy-cyclopentadecanone peak at tR = 15.08 min (m/z = 240.25 AMU, Δm/z = +16 
AMU) [106] 
Reported m/z = 240.2, 222.2, 207.2, 197.2, 179.2, 165.2, 151.1, 141.2, 127.1, 109.1, 95.1, 84.1, 81.1, 
67.1, 55.1. 
Experimental m/z = 240.25, 222.20, 207.05, 165.20, 151.1, 127.1, 109.15, 95.15, 81.10, 67.10, 55.05. 
 
Zoomed in version: 
 
 
MS analysis of minor product (cyclopentadecane-1,8-dione) at tR = 14.65 min (m/z = 238.3 AMU, Δm/z 
= +14 AMU) 
Reported m/z = 238.2, 220.2, 207.25, 181.2, 125.15, 112.1, 111.15, 98.15, 84.15, 83.10, 69.10, 55.10 
and 43.10 [106]. 




Figure B.8 (b): MS analysis of the substrate and oxidation metabolites generated in in vitro turnover 
of cyclopentadecanone with CYP101B1. 
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Figure B.9 (a): GCMS analysis of In vitro turnover of muscone by CYP101B1 (black) with substrate 
control (red). Internal standard is marked as (I.S.). Impurities are marked as (*). 
MS analysis of muscone substrate at tR = 13.12 min (m/z = 238.2 AMU).  
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MS analysis of metabolite at tR=15.45 min (m/z = 254 AMU; Δm/z = +16 AMU) 
 
 
Figure B.9 (b): MS analysis of the substrate and oxidation metabolites generated in in vitro turnover 
of muscone with CYP101B1. 
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Figure B.10 (a): GCMS analysis of In vitro turnover of oxacyclotridecan-2-one by CYP101B1 (black) 
with substrate control (red). Internal standard is marked as (I.S.). Impurities are marked as (*). 
MS analysis of oxacyclotridecan-2-one substrate at tR = 9.40 min (m/z = 198.05 AMU) 
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MS analysis of metabolite at tR=12.10 min (m/z = 214 AMU; Δm/z = +16 AMU) 
 
 
MS analysis of metabolite at tR=13.18 (m+/z = 214.1 AMU; Δm/z = +16 AMU) 
 
 
Figure B.10 (b): MS analysis of the substrate and oxidation metabolites generated in in vitro turnover 
of oxacyclotridecan-2-one with CYP101B1. 
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Figure B.11 (a): GCMS analysis of In vitro turnover of dihydroactinidiolide by CYP101B1 (black) with 
substrate control (red). Internal standard is marked as (I.S.). Impurities are marked as (*). 
MS analysis of dihydroactinidiolide substrate at tR = 9.41 min (m/z = 180.05 AMU) 
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MS analysis of metabolite at tR=12.21 min (m/z = 196.0 AMU; Δm/z = +16 AMU) 
 
 
MS analysis of metabolite at tR=12.28 min (m/z = 196.2 AMU; Δm/z = +16 AMU) 
 
 
Figure B.11 (b): MS analysis of the substrate and oxidation metabolites generated in in vitro turnover 
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Figure B.12 (a): GCMS analysis of In vitro turnover of trans-1-decalone with CYP101C1 (blue) in 
comparison with substrate control (red) and CYP101B1 (black). Internal standard is marked as (I.S.). 
Impurities are marked as (*). 
MS analysis of trans-1-decalone substrate at tR = 6.12 min (m/z = 152.100 AMU) 
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MS analysis of metabolite at tR = 7.38 min (m/z = 150.150 AMU; Δm/z = -2 AMU) 
 
 
MS analysis of metabolite at tR = 7.48 min (m/z = 167.900 AMU; Δm/z = +16 AMU) 
 
 
MS analysis of metabolite at tR = 7.75 min (m/z = 168.050 AMU; Δm/z = +16 AMU) 
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MS analysis of metabolite at tR =8.34 min (m/z = 168.100; Δm/z = +16 AMU) 
 
 
MS analysis of metabolite at tR = 10.04 min (m/z = 167.100 AMU; Δm/z = +15 AMU) 
 
 
Figure B.12 (b): MS analysis of the substrate and oxidation metabolites generated in in vitro turnover 
of trans-1-decalone with CYP101C1.  
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Figure B.13 (a): GCMS analysis of In vitro turnover of 2-decalone with CYP101C1 (blue) in comparison 
with substrate control (red) and CYP101B1 (black). Internal standard is marked as (I.S.). Impurities are 
marked as (*). 
MS analysis of 2-decalone substrate at tR = 6.25 min (m/z = 152.100 AMU) 
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MS analysis of metabolite at tR = 7.91 min (m/z = 150.100 AMU; Δm/z = -2 AMU) 
 
 
MS analysis of metabolite at tR = 8.01 min (m/z = 168.050 AMU; Δm/z = +16 AMU) 
 
 
MS analysis of metabolite at tR = 8.29 min (m/z = 168.100 AMU; Δm/z = +16 AMU) 
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MS analysis of metabolite at tR = 8.53 min (m/z = 168.050 AMU; Δm/z = +16 AMU) 
 
 
MS analysis of metabolite at tR = 8.91 min (m/z = 168.050 AMU; Δm/z = +16 AMU) 
 
 
Figure B.13 (b): MS analysis of the substrate and oxidation metabolites generated in in vitro turnover 
of 2-decalone with CYP101C1.  
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Figure B.14 (a): GCMS analysis of In vitro turnover of dihydroactinidiolide with CYP101C1 (blue) in 
comparison with substrate control (red) and CYP101B1 (black). Internal standard is marked as (I.S.). 
Impurities are marked as (*). 
MS analysis of dihydroactinidiolide substrate at tR = 9.45 min (m/z = 180 AMU) 
 
 
MS analysis of metabolite at tR = 10.03 min (m/z = 196.200 AMU; Δm/z = +16 AMU) 
 
 
Figure B.14 (b): MS analysis of the substrate and oxidation metabolites generated in in vitro turnover 
of dihydroactinidiolide with CYP101C1.  
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Figure B.15 (a): GCMS analysis of In vitro turnover of oxacyclotridecan-2-one with CYP101C1 (blue) in 
comparison with substrate control (red) and CYP101B1 (black). Internal standard is marked as (I.S.). 
Impurities are marked as (*). 
MS analysis of oxacyclotridecan-2-one substrate at tR = 9.43 min (m/z = 198.000 AMU) 
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MS analysis of metabolite at tR = 12.12 min (m/z = 212.900 AMU; Δm/z = +14 AMU) 
 
 
MS analysis of metabolite at tR = 13.17 min (m/z = 214.200 AMU; Δm/z = +16 AMU) 
 
 
Figure B.15 (b): MS analysis of the substrate and oxidation metabolites generated in in vitro turnover 
of oxacyclotridecan-2-one with CYP101C1.  
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Figure B.16: GCMS analysis of whole-cell turnover of oxacyclotridecan-2-one with CYP101B1 (blue) in 
comparison with substrate control (red) and in vitro turnover by CYP101B1 (black). 
 






















































Figure B.17: GCMS analysis of whole-cell turnover of dihydroactinidiolide with CYP101B1 (blue) in 
comparison with substrate control (red) and in vitro turnover by CYP101B1 (black). 
























































Figure B.18: GCMS analysis of whole-cell turnover of trans-1-decalone with CYP101B1 (blue) in 
comparison with substrate control (red) and in vitro turnover by CYP101B1 (black). 






















































Figure B.19: GCMS analysis of whole-cell turnover of 2-decalone with CYP101B1 (blue) in comparison 
with substrate control (red) and in vitro turnover by CYP101B1 (black). 
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Cyclopentadecanone: 
























































Figure B.20: GCMS analysis of whole-cell turnover of cyclopentadecanone with CYP101B1 (blue) in 
comparison with substrate control (red) and in vitro turnover by CYP101B1 (black). 
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Figure B.21 (a): 1H NMR data for product of Cyclopentadecanone in CDCl3. 
 
 
Figure B.21 (b): 13C NMR data for product of Cyclopentadecanone in CDCl3. 
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Figure B.21 (c): HSQC NMR data for product of Cyclopentadecanone in CDCl3. 
 
Figure B.21 (d): HMBC NMR data for product of Cyclopentadecanone in CDCl3. 
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Figure B.21 (e): g-COSY NMR data for product of Cyclopentadecanone in CDCl3. 
  




Figure B.22 (a): 1H NMR of product for oxacyclotridecan-2-one in CDCl3. 
 
 
Figure B.22 (b):13C NMR of product for oxacyclotridecan-2-one in CDCl3. 
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Figure B.22 (c): HSQC NMR of product for oxacyclotridecan-2-one in CDCl3. 
 
Figure B.22 (d): HMBC NMR of product for oxacyclotridecan-2-one in CDCl3. 
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Figure B.22 (e): g-COSY NMR of product for oxacyclotridecan-2-one in CDCl3. 
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6-hydroxy-dihydroactinidiolide: 1H NMR (500 MHz, CDCl3) δ 5.69 (s, 1H, H2), 4.32 (p, J = 3.48 Hz, 1H, 
H6), 2.46 (dt, J = 14.1, 2.6 Hz, 1H, H5), 1.97 (dt, J = 14.5, 2.58, 1H, H7), 1.80 – 1.76 (m, 4H, H5, H12), 
1.53 (dd, J = 14.3, 3.6 Hz, 1H, H7), 1.47 (s, 3H, H10), 1.27 (s, 3H, H11). 13C NMR (151 MHz, CDCl3) δ 
185.13 (C3), 174.57 (C1), 115.53 (C2), 89.37 (C4), 69.44 (C6), 49.94 (C7), 48.25 (C5), 38.58 (C4), 33.30 
(C10), 29.64 (C12), 29.12 (C11). 
  
 
Figure B.23 (a): 1H NMR for 6-hydroxy-dihydroactinidiolide in CDCl3. 
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Figure B.23 (b): 13C NMR for 6-hydroxy-dihydroactinidiolide in CDCl3. 
 
Figure B.23 (c): g-COSY NMR for 6-hydroxy-dihydroactinidiolide in CDCl3 





Figure B.23 (d): HSQC NMR for 6-hydroxy-dihydroactinidiolide in CDCl3. 





Figure B.23 (e): HMBC NMR for 6-hydroxy-dihydroactinidiolide in CDCl3. 
  
178 | P a g e  
 
7-hydroxy-p-tolyl acetate: 1H NMR (500 MHz, CDCl3) δ=7.38 (d, J = 8.4 Hz, 2H, H2, H6), 7.07 (d, J = 8.4 
Hz, 2H, H3, H5), 4.68 (s, 2H, H7), 2.30 (s, 3H, H10).  13C NMR (126 MHz, CDCl3) δ 172.18(C9), 
152.72(C4), 141.14(C1), 130.71(C2, C6), 124.32 (C3, C5), 67.40 (C7), 23.75 (C10). 
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Figure B.24 (b): 13C NMR for 7-hydroxy-p-tolyl acetate. 
 
Figure B.24 (c): HSQC NMR for 7-hydroxy-p-tolyl acetate. 
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Figure B.24 (d): HMBC NMR for 7-hydroxy-p-tolyl acetate. 
 
Figure B.24 (e): g-COSY NMR for 7-hydroxy-p-tolyl acetate. 
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6-hydroxy-trans-1-decalone:  
1H NMR (599 MHz, CDCl3) δ 3.41 – 3.36 (m, J = 10.3, 4.2 Hz, 1H, H6), 2.40 – 2.29 (m, 3H, H2, H2, H9), 
2.15 – 2.09 (m, 1H, H4), 2.04 – 1.99 (m, 1H, H10), 1.98 – 1.93 (m, 1H, H7), 1.89 – 1.84 (m, J = 8.5, 4.5 
Hz, 1H, H8), 1.84 – 1.79 (m, J = 8.6, 6.2, 2.9 Hz, 1H, H3), 1.68 – 1.59 (m, 1H, H4), 1.40 – 1.32 (m, 2H, 
H5, H9), 1.27 – 1.19 (m, 3H, H3, H7, H8). 13C NMR (151 MHz, CDCl3) δ 211.76 (C1), 75.07 (C6), 53.24 
(C10), 51.61 (C5), 41.54 (C2), 35.17 (C7), 28.21 (C9), 26.02 (C4), 24.58 (C8), 22.70 (C3). 
 
 
Figure B.25 (a): 1H NMR for 6-hydroxy-trans-1-decalone. 
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Figure B.25 (b): 13C NMR for 6-hydroxy-trans-1-decalone in CDCl3 
 
Figure B.25 (c): HSQC NMR for 6-hydroxy-trans-1-decalone in CDCl3. 
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Figure B.25 (d): HMBC NMR for 6-hydroxy-trans-1-decalone in CDCl3. 
 
 
Figure B.25 (e): g-COSY NMR for 6-hydroxy-trans-1-decalone in CDCl3. 
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Figure B.25 (f): DEPT NMR for 6-hydroxy-trans-1-decalone in CDCl3. This shows the 6 CH2 carbons (C2, 
C7, C9, C4, C8 and C3) and 3 CH carbons (C5, C6 and C10).   
CDCl3 
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7-hydroxy-trans-1-decalone: 1H NMR: 
1H NMR (500 MHz, CDCl3) δ 3.60 (ddd, J = 11.8, 9.2, 5.3 Hz, 1H, H7), 2.42 – 2.36 (m, 1H, H2), 2.30 (ddd, 
J = 13.7, 6.3, 1.2 Hz, 1H, H2), 2.23 – 2.17 (m, 1H, H6), 2.10 – 2.03 (m, 1H, H3), 2.02 – 1.97 (m, 2H, H4, 
H10), 1.85 (ddd, J = 13.5, 8.6, 4.4 Hz, 2H, H8/H9), 1.67 (dt, J = 13.0, 4.0 Hz, 1H, H3), 1.42 – 1.31 (m, 2H, 
H5, H8/H9), 1.28 – 1.20 (m, 4H, H4, H6, H8/H9). 13C NMR (126 MHz, CDCl3) δ 211.06 (C1), 70.49 (C7), 
52.87 (C10), 43.81 (C5), 41.35 (C2), 34.86 (C4), 34.58 (C6), 32.26 (C9/C8), 32.17 (C9/C8), 26.31 (C3). 
 
 
Figure B.26 (a): 1H NMR for 7-hydroxy-trans-1-decalone in CDCl3. 
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Figure B.26 (b): 13C NMR for 7-hydroxy-trans-1-decalone in CDCl3. 
 
Figure B.26 (c): HSQC NMR for 7-hydroxy-trans-1-decalone in CDCl3. 
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Figure B.26 (d): HMBC NMR for 7-hydroxy-trans-1-decalone in CDCl3. 
 
Figure B.26 (e): HMBC NMR for 7-hydroxy-trans-1-decalone in CDCl3. 
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Figure B.26 (f): g-COSY NMR for 7-hydroxy-trans-1-decalone in CDCl3.  
 
 
Figure B.26 (g): DEPT NMR for 7-hydroxy-trans-1-decalone in CDCl3. This shows the 6 CH2 carbons (C2, 
C6, C9, C4, C8 and C3) and 3 CH carbons (C5, C7 and C10). 
 
